🏷

Classifications

Harrison's Chapter

👪

Inheritance

1

X-linked recessive inheritance HP:0001419

AHDS is inherited in an X-linked manner. Hemizygous males carrying a pathogenic SLC16A2 variant are affected. Heterozygous females are usually not clinically affected but may show minor thyroid test abnormalities, with variability attributable to skewed X-inactivation.

X-linked recessive inheritance

Show evidence (3 references)

PMID:20301789 SUPPORT Human Clinical

"AHDS is inherited in an X-linked manner."

GeneReviews states the X-linked mode of inheritance directly.

PMID:20301789 SUPPORT Human Clinical

"females who inherit the variant will be heterozygotes (carriers) and usually will not be clinically affected but may have minor thyroid test abnormalities"

Documents the mild or absent carrier phenotype in heterozygous females, consistent with X-linked recessive inheritance modulated by X-inactivation.

PMID:14661163 SUPPORT Human Clinical

"Heterozygous females had a milder thyroid phenotype and no neurological defects."

The original gene-discovery families showed the same carrier pattern: biochemical abnormality without neurological disease in females.

?

Discussions and Knowledge Gaps

1

Does the Mct8 single-knockout mouse model the human cerebral phenotype of AHDS closely enough for its neurological readouts to be translated, given that it reproduces the human serum thyroid profile but develops without overt neurological deficits?

HUMAN MODEL MISMATCH OPEN ahds-mouse-model-mismatch

Attached to

Cerebral Thyroid Hormone Deprivation

This is a genuine translational mismatch rather than a gap in evidence. Mct8-null mice reproduce the human biochemical signature almost exactly (high T3, low T4, increased hepatic D1) and show reduced brain T3 uptake and a locally hypothyroid brain, yet they are neurologically near-normal and their cerebellar Purkinje cells develop normally. The accepted explanation is species difference in brain thyroid hormone transporter redundancy: mice express OATP1C1 at the blood-brain barrier as an alternative T4 route that humans rely on much less. Consequently the Mct8/Oatp1c1 double knockout, not the single knockout, is the appropriate model, and human iPSC-derived cerebral organoids are the strongest human-specific system. Any mouse-derived conclusion about the severity, reversibility, or therapeutic window of the human cerebral phenotype must be qualified accordingly.

Proposed experiments

Cross-model comparison of the cerebral deficit

ahds-cross-model-cerebral-deficit

Compare T3-responsive gene induction, oligodendrocyte maturation, and cortical unit thickness across Mct8 single-knockout mouse, Mct8/Oatp1c1 double-knockout mouse, and patient-derived human cerebral organoids under matched analogue treatment, to quantify how much of the human deficit each model captures.

Decision criterion

If the double-knockout mouse and human organoid converge on comparable deficits while the single knockout does not, the single knockout should be retired as a model of the human cerebral phenotype.

Therapeutic window mapping in human cerebral organoids

ahds-organoid-therapeutic-window

Apply Triac or DITPA to patient-derived cerebral organoids at staged developmental time points to define how late the MCT8-bypass strategy can still restore T3-responsive gene programs and cortical unit thickness.

Decision criterion

Identification of a developmental stage after which analogue treatment no longer restores T3-responsive gene induction would define the human therapeutic window and set the target age for early treatment.

Show evidence (2 references)

PMID:17318265 SUPPORT Model Organism

"In conclusion, the circulating thyroid hormone levels of MCT8-null mice closely resemble those of humans with MCT8 mutations, yet in the mice, CNS development is only partially affected."

States the mismatch explicitly: the mouse reproduces the human serum pattern but not the human CNS phenotype.

PMID:38376950 SUPPORT In Vitro

"Given species differences in brain TH transporters and the limitations of studies in mice, we generated cerebral organoids (COs) using human induced pluripotent stem cells (iPSCs) from MCT8-deficient patients."

Names species differences in brain thyroid hormone transporters and the limitations of mouse studies as the explicit motivation for building a human model, confirming the mismatch is recognised in the field.

⚙

Pathophysiology

8

SLC16A2 Loss of Function

Loss-of-function variants in SLC16A2 at Xq13.2 (deletions, nonsense, frameshift, and missense variants that misfold or mistraffic the protein) abolish or severely reduce the activity of monocarboxylate transporter 8 (MCT8), a 12-transmembrane-domain thyroid hormone-specific plasma membrane transporter. Because males are hemizygous, a single variant allele removes all functional transporter.

SLC16A2 hgnc:10923

Downstream

MCT8 Thyroid Hormone Transport Failure Absence of functional transporter protein directly abolishes MCT8-mediated cellular uptake of thyroid hormone.

Show evidence (3 references)

PMID:14661163 SUPPORT Human Clinical

"We now report, for the first time, mutations in the monocarboxylate transporter 8 (MCT8) gene, located on the X chromosome, that encodes a 613-amino acid protein with 12 predicted transmembrane domains."

Establishes SLC16A2/MCT8 as the mutated gene and describes the encoded 12-transmembrane-domain transporter.

PMID:15889350 SUPPORT Human Clinical

"linkage studies have placed the gene locus in Xq13.2. Mutations in the monocarboxylate transporter 8 gene (MCT8) have been found in each of the six families."

Confirms that the historically defined Allan-Herndon-Dudley families all carry MCT8 mutations at Xq13.2, anchoring disease identity to SLC16A2.

PMID:15488219 SUPPORT Human Clinical

"In two patients, gene deletions of 2.4 kb and 24 kb were recorded and in three patients missense mutations Ala150Val, Arg171 stop, and Leu397Pro were identified."

Documents the allelic spectrum, spanning whole-gene deletions through missense substitutions, all producing loss of function.

MCT8 Thyroid Hormone Transport Failure

MCT8 is a thyroid hormone-specific transporter that carries T3 and T4 across the plasma membrane. Its loss does not affect hormone synthesis or receptor function; it blocks hormone entry into cells. Critically, MCT8 dependence is tissue-selective. Brain barriers and many neurons rely on MCT8 as the rate-limiting import route, whereas liver, heart, and skeletal muscle import T3 through alternative transporters (MCT10, OATP family). This single lesion therefore partitions the body into hormone-deprived and hormone-overexposed compartments.

Thyroid Hormone Transport GO:0070327 ↓ DECREASED

Downstream

Cerebral Thyroid Hormone Deprivation Loss of MCT8-mediated transport across brain barriers and into neurons starves the CNS of thyroid hormone.

Signature Serum Iodothyronine Pattern Blocked cellular uptake and altered peripheral deiodinase handling shift circulating iodothyronines toward high T3 with low free T4.

Show evidence (3 references)

PMID:15488219 SUPPORT Human Clinical

"We suggest that this novel syndrome of X-linked psychomotor retardation is due to a defect in T3 entry into neurons through MCT8, resulting in impaired T3 action and metabolism."

States the core mechanism: failure of T3 entry into neurons through MCT8 rather than any defect of hormone production or receptor action.

PMID:15889350 SUPPORT Human Clinical

"One essential function of the protein encoded by this gene appears to be the transport of triiodothyronine into neurons."

Identifies neuronal T3 import as the essential MCT8 function that is lost.

clinicaltrials:NCT02060474 SUPPORT Other

"MCT8 is a thyroid hormone (TH) transporter which is crucial for the transport of TH from the blood into different tissues. Dysfunction of MCT8 results in a lack of TH (hypothyroidism) in tissues that depend on MCT8 for TH uptake."

States the tissue-selective logic of MCT8 dependence that underlies the simultaneous two-compartment phenotype.

Cerebral Thyroid Hormone Deprivation

Brain thyroid hormone content falls despite normal or elevated circulating T3, because MCT8 is the rate-limiting import step at the blood-brain barrier and in MCT8-dependent neurons. The CNS therefore behaves as a hypothyroid tissue: T3-responsive gene programs are under-driven, and compensatory deiodinase changes (increased DIO2, decreased DIO3) fail to restore local hormone supply. This is the one conserved step AHDS shares with classical hypothyroidism, and the only node here that declares module conformance.

Response to Thyroid Hormone GO:0097066 ↓ DECREASED

Downstream

Impaired Oligodendrocyte Maturation and Hypomyelination Thyroid hormone is the timing signal for oligodendrocyte precursor differentiation; without it, myelination is delayed.

Disrupted Neuronal and Cerebellar Development T3-dependent programs governing GABAergic interneuron, cortical, and cerebellar maturation are under-driven.

Show evidence (4 references)

PMID:32559475 SUPPORT Human Clinical

"Disordered thyroid hormone transport, due to mutations in the SLC16A2 gene encoding monocarboxylate transporter 8 (MCT8), is characterised by intellectual and motor disability resulting from cerebral hypothyroidism and chronic peripheral thyrotoxicosis."

Names cerebral hypothyroidism as the direct cause of the intellectual and motor disability, alongside the simultaneous peripheral thyrotoxicosis.

clinicaltrials:NCT02060474 SUPPORT Other

"This local hypothyroidism in the brain of these patients causes severe psychomotor retardation."

States the causal link from local (brain-restricted) hypothyroidism to the severe neurodevelopmental phenotype.

PMID:17318265 SUPPORT Model Organism

"In the mutants' brains, entry of T4 was not affected, but uptake of T3 was diminished. Moreover, the T4 and T3 content in the brain of MCT8-null mice was decreased, the activity of D2 was increased, and D3 activity was decreased, indicating the hypothyroid state of this tissue."

Direct experimental demonstration in Mct8-null mice that brain T3 uptake and brain hormone content fall, with the deiodinase shifts that define a locally hypothyroid tissue. Mouse evidence; the murine CNS phenotype is milder than the human one.

+ 1 more reference

Impaired Oligodendrocyte Maturation and Hypomyelination

Thyroid hormone provides the temporal cue that drives oligodendrocyte precursor cells to exit the progenitor state and become mature, myelinating oligodendrocytes. In MCT8 deficiency the precursor pool expands while mature oligodendrocyte numbers fall, a differentiation block that produces reduced myelin content, a shift toward small-caliber myelinated axons, and the global delay in myelination seen on MRI in essentially every patient.

Oligodendrocyte CL:0000128 Oligodendrocyte Precursor Cell CL:0002453

Oligodendrocyte Differentiation GO:0048709 ↓ DECREASED Myelination GO:0042552 ↓ DECREASED

Downstream

Delayed myelination The oligodendrocyte differentiation block manifests radiologically as a global delay in myelination.

Spastic tetraplegia Deficient myelination of corticospinal projections contributes to the pyramidal signs that supersede infantile hypotonia.

Inability to walk Combined hypomyelination of motor pathways and central motor under-development leaves most affected males unable to walk independently.

Show evidence (3 references)

PMID:37307933 SUPPORT Model Organism

"Proper CNS myelination depends on the timed availability of thyroid hormone (TH) that induces differentiation of oligodendrocyte precursor cells (OPCs) to mature, myelinating oligodendrocytes."

Establishes the thyroid-hormone dependence of the OPC-to-oligodendrocyte transition that fails when brain hormone supply is lost.

PMID:37307933 SUPPORT Model Organism

"Dko mice exhibited at all analysed time points an increased portion of OPCs and a reduced number of mature oligodendrocytes both in white and grey matter regions indicating a differentiation blockage in the absence of Mct8/Oatp1c1."

Demonstrates the specific cellular lesion, an oligodendrocyte differentiation block, in the Mct8/Oatp1c1 double-knockout model of human MCT8 deficiency.

PMID:34838669 SUPPORT Human Clinical

"the MCT8-deficient subject presents severely reduced myelin lipid and protein staining and increased proportion of small-caliber myelinated axons in detriment of large-caliber ones"

Human post-mortem brain histology confirms that the myelin deficit and axonal caliber shift are real features of MCT8-deficient human brain, not only of the mouse model.

Disrupted Neuronal and Cerebellar Development

Beyond myelin, thyroid hormone drives neuronal migration, dendritic arborization, GABAergic interneuron maturation, and cerebellar granule and Purkinje cell development. Loss of brain hormone supply during the critical developmental window leaves these programs incomplete and irreversible, which is why the few motor and cognitive abilities patients acquire do not improve with age.

GABAergic Interneuron CL:0000617 Cerebellar Purkinje Cell CL:0000121

Central Nervous System Development GO:0007417 ⚠ ABNORMAL

Downstream

Severe intellectual disability Failure of T3-dependent cortical development produces severe cognitive impairment.

Axial hypotonia Immature central motor control presents in infancy as truncal hypotonia and absent head control.

Dystonia Under-development of basal ganglia and interneuron circuits produces extrapyramidal movement abnormalities.

Choreoathetosis Extrapyramidal circuit immaturity also produces choreoathetoid posturing.

Absent speech Severe global neurodevelopmental failure leaves most patients without speech.

Seizure Disrupted excitatory-inhibitory balance from impaired GABAergic development predisposes to often drug-resistant seizures.

Feeding difficulties Immature bulbar and oromotor control produces infantile feeding difficulty and excessive drooling.

Dysphagia The same bulbar and oromotor deficit impairs swallowing, predisposing to aspiration.

Aspiration pneumonia Aspiration of food and secretions across an incompetent swallow produces the pulmonary infection that is the leading cause of death.

Nystagmus Immature central oculomotor and cerebellar control produces rotary nystagmus and impaired gaze.

Scoliosis Truncal hypotonia, spasticity, and absent independent ambulation combine to produce neuromuscular scoliosis.

Hip dislocation The same abnormal tone and absence of weight-bearing predispose to hip dysplasia and dislocation.

Show evidence (3 references)

PMID:32559475 SUPPORT Human Clinical

"The few motor and cognitive abilities of patients did not improve with age, as evidenced by the absence of significant correlations between biological age and scores on the Gross Motor Function Measure-88 and Bayley Scales of Infant Development III."

Documents the fixed, non-progressive developmental ceiling expected from a failure of a time-limited developmental program rather than an ongoing degenerative process.

PMID:14661163 SUPPORT Human Clinical

"Thyroid hormones are iodothyronines that control growth and development, as well as brain function and metabolism."

States the developmental role of thyroid hormone in the brain whose interruption underlies the neurodevelopmental phenotype.

PMID:17318265 PARTIAL Model Organism

"however, cerebellar Purkinje cells appeared unaffected, since they did not exhibit dendritic outgrowth defects and responded normally to T3 treatment in vitro"

Marked PARTIAL because it qualifies rather than supports the cerebellar arm: single Mct8 knockout mice spare Purkinje cell dendritic development, which is why the mouse CNS phenotype is milder than the human disease and why Mct8/Oatp1c1 double knockouts are the better model.

Signature Serum Iodothyronine Pattern

The diagnostic biochemical triad is high serum T3 with low or low-normal free T4 and a normal or only mildly elevated TSH, giving an increased T3/T4 ratio and low reverse T3. This pattern arises because tissues that retain hormone uptake (notably liver) increase type 1 deiodinase activity, converting T4 to T3, while the pituitary and hypothalamus receive a mixed signal, so TSH is not suppressed to the degree the elevated T3 would predict. The combination is what distinguishes AHDS from ordinary primary hypothyroidism (low T3 and T4 with high TSH) and from thyroid hormone resistance syndromes, and it is the diagnostic key.

Thyroid Hormone Metabolic Process GO:0042403 ⚠ ABNORMAL

Downstream

Peripheral Thyrotoxicosis in MCT8-Independent Tissues The elevated circulating T3 is freely taken up by tissues that do not depend on MCT8, over-stimulating them.

Increased circulating free T3 The serum pattern is measured directly as elevated free and total T3.

Decreased circulating free T4 concentration Enhanced T4-to-T3 conversion lowers circulating free thyroxine.

Inappropriately normal thyroid-stimulating hormone level TSH fails to fall as the elevated T3 would predict, because pituitary hormone sensing is itself partly MCT8-dependent.

Increased T3/T4 ratio The divergence of T3 and T4 raises the T3/T4 ratio, a derived diagnostic index.

Decreased circulating reverse T3 concentration The shift of peripheral deiodination away from the inactivating type 3 pathway lowers circulating reverse T3.

Show evidence (4 references)

clinicaltrials:NCT02060474 SUPPORT Other

"In addition, TH serum parameters are highly abnormal in AHDS: high T3, low T4 and normal TSH levels."

States the signature triad explicitly.

PMID:32559475 SUPPORT Human Clinical

"Tri-iodothyronine concentrations were above the age-specific upper limit in 96 (95%) of 101 patients and free thyroxine concentrations were below the age-specific lower limit in 94 (89%) of 106 patients."

Quantifies the penetrance of the high-T3, low-free-T4 pattern in the largest genetically confirmed cohort assembled.

PMID:15889350 SUPPORT Human Clinical

"Abnormal transporter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood."

Links the serum pattern directly to the transporter defect.

+ 1 more reference

Peripheral Thyrotoxicosis in MCT8-Independent Tissues

Liver, heart, kidney, and skeletal muscle import T3 through MCT10, OATP, and other non-MCT8 routes, so they are fully exposed to the elevated circulating T3. These tissues are therefore chronically thyrotoxic while the brain is hypothyroid. This is the mechanistic reason why levothyroxine or liothyronine replacement is harmful in AHDS: extra hormone cannot reach the brain but does reach and further over-stimulate the periphery.

Response to Thyroid Hormone GO:0097066 ↑ INCREASED

Downstream

Hypermetabolism and Muscle Wasting Excess T3 action in peripheral tissues raises metabolic rate and drives catabolism.

Show evidence (2 references)

clinicaltrials:NCT02060474 SUPPORT Other

"The high serum T3 levels cause local hyperthyroidism in tissues that do not depend on MCT8 for cellular transport of TH, resulting in a low body weight and reduced muscle mass."

States the peripheral-thyrotoxicosis arm and its anthropometric consequences, in explicit contrast to the hypothyroid brain.

PMID:31377265 SUPPORT Human Clinical

"This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected individuals to substantial morbidity and mortality."

Establishes chronic peripheral thyrotoxicosis as the driver of the systemic morbidity and of excess mortality.

Hypermetabolism and Muscle Wasting

Sustained peripheral T3 excess raises basal metabolic rate, increases resting heart rate and systolic blood pressure, elevates sex hormone-binding globulin, lowers serum creatinine from reduced muscle mass, and produces a progressive negative energy balance that manifests as failure to thrive and muscle wasting. Being underweight in early childhood is an independent predictor of mortality, so this arm is not merely cosmetic.

Regulation of Metabolic Process GO:0019222 ↑ INCREASED

Downstream

Failure to thrive Negative energy balance from hypermetabolism produces poor weight gain.

Decreased muscle mass Catabolic T3 excess in skeletal muscle drives muscle wasting.

Tachycardia Excess T3 action on MCT8-independent cardiac tissue raises resting heart rate.

Premature atrial contractions The same unopposed atrial T3 action produces ectopic atrial automaticity and premature atrial contractions.

Elevated systolic blood pressure Increased cardiac output and reduced systemic vascular resistance from peripheral T3 excess raise systolic blood pressure.

Show evidence (3 references)

PMID:22993035 SUPPORT Human Clinical

"The great majority of affected children cannot walk or talk, and all have elevated serum T(3) levels, causing peripheral tissue hypermetabolism and inability to maintain weight."

Links elevated serum T3 causally to peripheral hypermetabolism and the inability to maintain weight.

PMID:32559475 SUPPORT Human Clinical

"Patients who were underweight during age 1-3 years had an increased risk for death compared with patients who were of normal bodyweight at this age (HR 4·71, 95% CI 1·26-17·58, p=0·021)."

Shows the hypermetabolic-catabolic arm is prognostically important, not incidental, which is the rationale for treating peripheral thyrotoxicosis.

PMID:34679181 SUPPORT Human Clinical

"Patients with mutations in thyroid hormone transporter MCT8 have developmental delay and chronic thyrotoxicosis associated with being underweight and having cardiovascular dysfunction."

Associates chronic thyrotoxicosis with the underweight state and cardiovascular dysfunction that define this node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

25

Cardiovascular 1

Tachycardia FREQUENT Tachycardia HP:0001649

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"25 (53%) of 47 patients had elevated systolic blood pressure above the 90th percentile, 34 (76%) of 45 patients had premature atrial contractions, and 20 (31%) of 64 had resting tachycardia."

Quantifies resting tachycardia at 31%, supporting the FREQUENT band, and documents the associated cardiovascular findings.

Digestive 2

Feeding difficulties FREQUENT Feeding difficulties HP:0011968

Show evidence (1 reference)

PMID:20301789 SUPPORT Human Clinical

"hypotonia and feeding difficulties in infancy"

GeneReviews names feeding difficulties as an infantile feature.

Dysphagia FREQUENT Dysphagia HP:0002015

Show evidence (2 references)

PMID:39132310 PARTIAL Other

"multidisciplinary team care is vital to optimize the support provided to patients and their caregivers"

Marked PARTIAL: this review supports the need for multidisciplinary (including feeding and nutrition) care, but the retrieved abstract does not itself quantify swallowing impairment. The mechanistic link to aspiration pneumonia is supported separately by the cohort mortality data.

PMID:32559475 PARTIAL Human Clinical

"32 (21%) of 151 patients died; the main causes of mortality in these patients were pulmonary infection"

Marked PARTIAL: supports the clinical significance of aspiration-prone swallowing (pulmonary infection is the leading cause of death) rather than directly quantifying dysphagia frequency.

Eye 1

Nystagmus Nystagmus HP:0000639

Show evidence (1 reference)

PMID:14661163 SUPPORT Human Clinical

"neurological abnormalities, including global developmental delay, central hypotonia, spastic quadriplegia, dystonic movements, rotary nystagmus, and impaired gaze and hearing"

Names rotary nystagmus among the defining neurological abnormalities of the original MCT8-mutant probands. No frequency is stated in any cited source, so no frequency band is asserted.

Immune 1

Aspiration pneumonia Aspiration pneumonia HP:0011951

Show evidence (2 references)

PMID:39132310 SUPPORT Other

"are at risk of aspiration pneumonia, so swallowing function should be regularly assessed via speech therapy and radiographic swallowing studies"

States that children with MCT8 deficiency are at risk of aspiration pneumonia and that this risk is the rationale for swallowing surveillance. No prevalence figure is given, so no frequency band is asserted.

PMID:32559475 SUPPORT Human Clinical

"32 (21%) of 151 patients died; the main causes of mortality in these patients were pulmonary infection"

Establishes pulmonary infection as a leading cause of death in the largest genetically confirmed cohort, quantifying the clinical consequence of the aspiration risk. It reports cause-of-death share rather than phenotype prevalence, so it does not license a frequency band.

Musculoskeletal 1

Scoliosis Scoliosis HP:0002650

Show evidence (2 references)

PMID:20301789 SUPPORT Human Clinical

"spine for scoliosis and hips for dislocation"

GeneReviews names scoliosis as a specific surveillance target in AHDS, establishing it as an expected complication. No frequency is reported, so no frequency band is asserted.

PMID:39132310 SUPPORT Other

"patients should be evaluated for scoliosis, which may impede respiratory function and sleep"

Independently recommends scoliosis evaluation and states its functional consequence in MCT8 deficiency.

Nervous System 6

Severe intellectual disability VERY_FREQUENT Severe intellectual disability HP:0010864

Show evidence (2 references)

PMID:15889350 SUPPORT Human Clinical

"Cognitive development is severely impaired."

States the severity of cognitive impairment in the classic AHDS families.

PMID:20301789 SUPPORT Human Clinical

"developmental delay / intellectual disability ranging from mild to profound"

GeneReviews documents developmental delay and intellectual disability as a defining feature, with a range extending to profound.

Dystonia FREQUENT Dystonia HP:0001332

Show evidence (1 reference)

PMID:20301789 SUPPORT Human Clinical

"extrapyramidal findings (dystonia, choreoathetosis, paroxysmal movement disorder, hypokinesia, masked facies)"

GeneReviews enumerates the extrapyramidal features, dystonia first among them.

Choreoathetosis FREQUENT Choreoathetosis HP:0001266

Show evidence (2 references)

PMID:20301789 SUPPORT Human Clinical

"extrapyramidal findings (dystonia, choreoathetosis, paroxysmal movement disorder, hypokinesia, masked facies)"

GeneReviews lists choreoathetosis among the extrapyramidal findings.

PMID:15889350 SUPPORT Human Clinical

"The hands exhibit dystonic and athetoid posturing and fisting."

Describes the characteristic athetoid hand posturing.

Absent speech FREQUENT Absent speech HP:0001344

Show evidence (2 references)

PMID:15889350 SUPPORT Human Clinical

"Speech is dysarthric or absent altogether."

Documents absent or severely dysarthric speech.

PMID:22993035 SUPPORT Human Clinical

"The great majority of affected children cannot walk or talk"

Confirms that the great majority of affected children never acquire speech.

Seizure OCCASIONAL Seizure HP:0001250

Show evidence (1 reference)

PMID:20301789 SUPPORT Human Clinical

"and seizures, often with drug resistance"

GeneReviews identifies seizures with frequent drug resistance as part of the clinical spectrum.

Delayed myelination VERY_FREQUENT Delayed myelination HP:0012448

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"The most consistent MRI finding was a global delay in myelination, which occurred in 13 (100%) of 13 patients."

Directly supports both the finding and the VERY_FREQUENT band (13 of 13 imaged patients).

Growth 1

Failure to thrive FREQUENT Failure to thrive HP:0001508

Show evidence (2 references)

PMID:32559475 SUPPORT Human Clinical

"59 (71%) of 83 patients were underweight."

Quantifies the underweight state at 71%, supporting the FREQUENT band (30-79%).

PMID:20301789 SUPPORT Human Clinical

"dysthyroidism (manifest as poor weight gain, reduced muscle mass, and variable cold intolerance, sweating, elevated heart rate, and irritability)"

GeneReviews attributes poor weight gain specifically to the dysthyroid (peripheral thyrotoxic) state.

Other 12

Axial hypotonia VERY_FREQUENT Axial hypotonia HP:0008936

Temporal: TRANSIENT

Show evidence (2 references)

PMID:14661163 SUPPORT Human Clinical

"neurological abnormalities, including global developmental delay, central hypotonia, spastic quadriplegia, dystonic movements, rotary nystagmus, and impaired gaze and hearing"

Lists central hypotonia among the defining neurological abnormalities.

PMID:20301789 SUPPORT Human Clinical

"hypotonia and feeding difficulties in infancy"

GeneReviews establishes infantile hypotonia as a presenting feature.

Spastic tetraplegia FREQUENT Spastic tetraplegia HP:0002510

Course: PROGRESSIVE

Show evidence (2 references)

PMID:15889350 SUPPORT Human Clinical

"Hypotonia gives way in adult life to spasticity."

Documents the characteristic evolution from infantile hypotonia to spasticity.

PMID:14661163 SUPPORT Human Clinical

"central hypotonia, spastic quadriplegia, dystonic movements"

Names spastic quadriplegia in the original gene-discovery probands.

Inability to walk FREQUENT Inability to walk HP:0002540

Show evidence (2 references)

PMID:15889350 SUPPORT Human Clinical

"Generalized weakness is manifested by excessive drooling, forward positioning of the head and neck, failure to ambulate independently, or ataxia in those who do ambulate."

Documents failure of independent ambulation, with ataxia in the minority who walk.

PMID:22993035 SUPPORT Human Clinical

"The great majority of affected children cannot walk or talk"

Confirms the high frequency of non-ambulation.

Decreased muscle mass VERY_FREQUENT Decreased muscle mass HP:0003199

Show evidence (2 references)

PMID:15889350 SUPPORT Human Clinical

"Infancy and childhood in the Allan-Herndon-Dudley syndrome are marked by hypotonia, weakness, reduced muscle mass, and delay of developmental milestones."

Names reduced muscle mass among the cardinal early features.

PMID:31377265 SUPPORT Human Clinical

"This chronic thyrotoxicosis leads to progressive deterioration in bodyweight, tachycardia, and muscle wasting"

Attributes the muscle wasting causally to the chronic peripheral thyrotoxicosis.

Hip dislocation Hip dislocation HP:0002827

Show evidence (2 references)

PMID:20301789 SUPPORT Human Clinical

"spine for scoliosis and hips for dislocation"

GeneReviews names hip dislocation as a specific surveillance target in AHDS. No frequency is reported, so no frequency band is asserted.

PMID:39132310 SUPPORT Other

"Orthopedic specialists should be consulted to assess for hip dysplasia, which may cause discomfort"

Independently recommends orthopaedic assessment for hip dysplasia in MCT8 deficiency.

Premature atrial contractions FREQUENT Premature atrial contractions HP:0006699

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"34 (76%) of 45 patients had premature atrial contractions"

Quantifies premature atrial contractions at 76% of assessed patients, which falls in the FREQUENT band (79-30%).

Elevated systolic blood pressure FREQUENT Elevated systolic blood pressure HP:0004421

Show evidence (2 references)

PMID:32559475 SUPPORT Human Clinical

"25 (53%) of 47 patients had elevated systolic blood pressure above the 90th percentile"

Quantifies elevated systolic blood pressure at 53% of assessed patients, which falls in the FREQUENT band (79-30%).

PMID:20301789 SUPPORT Human Clinical

"decreased heart rate, systolic blood pressure, and hypertension"

GeneReviews reports that systolic blood pressure and hypertension fall on TRIAC, confirming that the elevated pressure is driven by the treatable peripheral thyrotoxicosis.

Increased circulating free T3 VERY_FREQUENT Increased circulating free T3 HP:0011788

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"Tri-iodothyronine concentrations were above the age-specific upper limit in 96 (95%) of 101 patients"

Quantifies elevated T3 in 95% of tested patients, supporting the VERY_FREQUENT band.

Decreased circulating free T4 concentration VERY_FREQUENT Decreased circulating free T4 concentration HP:0033078

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"free thyroxine concentrations were below the age-specific lower limit in 94 (89%) of 106 patients"

Quantifies low free T4 in 89% of tested patients, supporting the VERY_FREQUENT band.

Inappropriately normal thyroid-stimulating hormone level VERY_FREQUENT Inappropriately normal thyroid-stimulating hormone level HP:0033075

Show evidence (1 reference)

clinicaltrials:NCT02060474 SUPPORT Other

"TH serum parameters are highly abnormal in AHDS: high T3, low T4 and normal TSH levels."

States the normal TSH in the presence of high T3, the third element of the diagnostic triad.

Increased T3/T4 ratio VERY_FREQUENT Increased T3/T4 ratio HP:0012559

Show evidence (1 reference)

PMID:15889350 SUPPORT Human Clinical

"Abnormal transporter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood."

The simultaneous elevation of T3 and reduction of T4 described here is exactly what an increased T3/T4 ratio measures.

Decreased circulating reverse T3 concentration Decreased circulating reverse T3 concentration HP:6001334

Show evidence (2 references)

PMID:39132310 SUPPORT Other

"The only characteristic MCT8-related thyroid hormone alteration that is present within the newborn period is a low reverse T3 (rT3)"

Establishes the low reverse T3 as a characteristic MCT8-deficiency alteration and the only one detectable in the newborn period. No prevalence figure is given, so no frequency band is asserted.

PMID:22993035 SUPPORT Human Clinical

"DITPA normalized the elevated serum T(3) and TSH when the dose reached 1 mg/kg · d and T(4) and rT(3) increased to the lower normal range."

That reverse T3 rose INTO the lower normal range on treatment establishes that it was subnormal in untreated AHDS.

🧬

Genetic Associations

1

SLC16A2 (Loss-of-function variants)

Gene: SLC16A2 hgnc:10923 relationship_type: CAUSATIVE

Show evidence (6 references)

PMID:15889350 SUPPORT Human Clinical

"Six large families with the syndrome have been identified, and linkage studies have placed the gene locus in Xq13.2. Mutations in the monocarboxylate transporter 8 gene (MCT8) have been found in each of the six families."

Establishes SLC16A2/MCT8 at Xq13.2 as the cause in every historically defined Allan-Herndon-Dudley family.

PMID:14661163 SUPPORT Human Clinical

"These findings establish the physiological importance of MCT8 as a thyroid hormone transporter."

Original gene-discovery paper establishing MCT8 as the disease gene.

PMID:32559475 SUPPORT Human Clinical

"we enrolled 151 patients with 73 different MCT8 (SLC16A2) mutations"

Demonstrates the wide allelic heterogeneity, with 73 distinct variants across 151 genetically confirmed patients.

+ 3 more references

💊

Medical Actions

6

Tiratricol (Triac)

Action: Pharmacotherapy NCIT:C15986

Agent: tiratricol CHEBI:40021

Triac (3,3',5-triiodothyroacetic acid, tiratricol) is a T3 analogue that binds the same thyroid hormone receptors as T3 but enters cells independently of MCT8. It is the rational therapy for AHDS: it suppresses the pituitary, lowering the elevated serum T3 and thereby relieving peripheral thyrotoxicosis, and can in principle reach MCT8-dependent tissues that T3 cannot. In the international phase 2 Triac Trial (46 patients), serum T3 fell from 4.97 to 1.82 nmol/L over 12 months with only transient adverse effects; a real-life cohort of 67 patients treated up to 6 years confirmed sustained benefit with gains in body weight, reductions in heart rate, and falling SHBG. Evidence that Triac reverses the cerebral hypothyroidism is much weaker than the evidence for peripheral benefit, and is the question Triac Trial II was designed to answer by treating boys aged 30 months or younger.

Mechanism Target:

INHIBITS Peripheral Thyrotoxicosis in MCT8-Independent Tissues — By suppressing TSH and lowering circulating T3, Triac removes the excess hormone driving MCT8-independent tissues, which is the arm of the disease it demonstrably improves.

INHIBITS Cerebral Thyroid Hormone Deprivation — Triac enters cells without MCT8 and can therefore in principle substitute for T3 in MCT8-dependent brain tissue. This is the therapeutic rationale but remains the less well demonstrated of the two effects.

Target Phenotypes: Elevated serum T3 HP:0011788 Failure to thrive / underweight HP:0001508 Resting tachycardia HP:0001649

Show evidence (5 references)

clinicaltrials:NCT02060474 SUPPORT Other

"Cellular uptake of Triac does not depend on functional MCT8."

States the pharmacological property that makes Triac rational in a transport-defect disease.

PMID:31377265 SUPPORT Human Clinical

"Key features of peripheral thyrotoxicosis were alleviated in paediatric and adult patients with MCT8 deficiency who were treated with Triac. Triac seems a reasonable treatment strategy to ameliorate the consequences of untreated peripheral thyrotoxicosis in patients with MCT8 deficiency."

Primary trial conclusion: Triac alleviates peripheral thyrotoxicosis. Note the deliberately limited claim, confined to the peripheral arm.

PMID:34679181 SUPPORT Human Clinical

"Key features were sustainably alleviated in patients with MCT8 deficiency across all ages, highlighting the real-life potential of Triac for MCT8 deficiency."

Long-term real-life cohort confirming durability of benefit over up to six years.

+ 2 more references

Diiodothyropropionic acid (DITPA)

Action: Pharmacotherapy NCIT:C15986

Agent: diiodothyropropionic acid CHEBI:134267

DITPA is a second MCT8-independent thyroid hormone analogue. In four children treated on compassionate grounds for 26-40 months, DITPA normalized elevated serum T3 and TSH, raised T4 and reverse T3 into the low normal range, and reduced SHBG and heart rate without adverse effects. Evidence is far more limited than for Triac and DITPA is not in routine use, but it establishes that the MCT8-bypass strategy generalizes beyond a single compound.

Mechanism Target:

INHIBITS Peripheral Thyrotoxicosis in MCT8-Independent Tissues — DITPA lowers circulating T3 and reduces markers of peripheral hypermetabolism such as SHBG and heart rate.

Show evidence (2 references)

PMID:22993035 SUPPORT Human Clinical

"DITPA (1-2 mg/kg · d) almost completely normalizes thyroid tests and reduces the hypermetabolism and the tendency for weight loss."

Conclusion of the compassionate-use series in four children, supporting DITPA as an alternative MCT8-independent analogue.

PMID:22993035 SUPPORT Model Organism

"In Mct8-deficient mice, the thyroid hormone analog, diiodothyropropionic acid (DITPA), does not require MCT8 to enter tissues and could be an effective alternative to thyroid hormone treatment in humans."

States the preclinical MCT8-independence rationale established in Mct8-deficient mice.

Thyroid hormone replacement (levothyroxine or liothyronine) - contraindicated as monotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: levothyroxine CHEBI:30660

Standard thyroid hormone replacement fails in AHDS and is harmful. Levothyroxine or liothyronine cannot cross into MCT8-dependent brain tissue, so the cerebral hypothyroidism is not corrected, while the additional hormone is fully available to MCT8-independent peripheral tissues and therefore aggravates the existing thyrotoxicosis and hypermetabolism. GeneReviews lists administration of L-T4 or L-T3 alone under agents and circumstances to avoid. This is the single most important management point in the disease and the reason the correct diagnosis matters: a boy with developmental delay and a low free T4 will otherwise be given levothyroxine.

Show evidence (3 references)

PMID:20301789 SUPPORT Human Clinical

"Agents/circumstances to avoid: Administration of L-T4 or L-T3 alone can exacerbate the high serum T3 levels and the resulting hypermetabolism."

GeneReviews drug-safety warning naming L-T4 and L-T3 monotherapy as agents to avoid.

PMID:20301789 SUPPORT Human Clinical

"Thyroid hormone replacement therapy during childhood has no beneficial effect and could be dangerous by worsening dysthyroidism."

States both the lack of benefit and the potential harm of conventional replacement.

PMID:22993035 SUPPORT Human Clinical

"Treatment with thyroid hormone is ineffective."

Independent confirmation that conventional thyroid hormone is ineffective.

Multidisciplinary supportive and rehabilitative care

Action: Supportive Care NCIT:C15747

There is no disease-modifying therapy for the neurological phenotype, so management is supportive: physiotherapy and positioning for hypotonia and spasticity, management of extrapyramidal movement disorders, nutritional support (including gastrostomy where feeding difficulty and weight loss demand it), and surveillance for scoliosis and hip dislocation.

Show evidence (2 references)

PMID:20301789 SUPPORT Human Clinical

"Multidisciplinary team to provide standard care for hypotonia, poor feeding, DD/ID, spasticity, and extrapyramidal movement disorders."

GeneReviews management recommendation for multidisciplinary supportive care.

PMID:20301789 SUPPORT Human Clinical

"Surveillance: In children, assess the following every six months until age four years, then once a year: developmental progress & educational needs; neurologic examination for new manifestations"

Documents the recommended surveillance schedule.

Anti-seizure medication

Action: Anticonvulsant Therapy NCIT:C64172

Seizures are managed with standard anti-seizure medication under an experienced neurologist, but drug resistance is common.

Target Phenotypes: Seizures, often drug-resistant HP:0001250

Show evidence (1 reference)

PMID:20301789 SUPPORT Human Clinical

"Standard treatment with anti-seizure medication by an experienced neurologist."

GeneReviews management recommendation for the seizure phenotype.

Genetic counseling and carrier testing

Action: Genetic Counseling NCIT:C15240

Because AHDS is X-linked, carrier testing of at-risk female relatives, prenatal testing, and preimplantation genetic testing become available once the familial SLC16A2 variant is known. A carrier mother has a 50% chance of transmitting the variant in each pregnancy.

Show evidence (3 references)

PMID:20301789 SUPPORT Human Clinical

"Once the SLC16A2 pathogenic variant has been identified in an affected family member, carrier testing of at-risk female relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."

GeneReviews genetic counseling guidance.

PMID:20301789 SUPPORT Human Clinical

"If the mother of a proband has an SLC16A2 pathogenic variant, the chance of transmitting it in each pregnancy is 50%."

GeneReviews states the 50% per-pregnancy transmission risk verbatim, sourcing the figure asserted in this treatment description.

PMID:39132310 SUPPORT Other

"there is a 50% chance that male children will be affected if their mother is a carrier of a pathogenic SLC16A2 mutation"

Independently states the sex-specific consequence of the 50% transmission risk in this X-linked disorder.

🔬

Biochemical Markers

5

Serum total triiodothyronine (T3) (INCREASED)

Reference Ranges

Triiodothyronine (T3) [Moles/volume] in Serum or Plasma 1.4–2.5 nmol/L (Reference target range used in the international Triac Trial for paediatric and adult males with MCT8 deficiency.)

Normal (1.4–2.5 nmol/L) Elevated T3 typical of untreated MCT8 deficiency (2.5– nmol/L) → Increased circulating free T3

Normal: Within the target range used in the Triac trials. Untreated AHDS essentially never falls here; a normal T3 on treatment is the therapeutic goal.

Elevated T3 typical of untreated MCT8 deficiency: An elevated T3 in a boy with severe developmental delay and hypotonia should prompt free T4, TSH, and SLC16A2 sequencing. Untreated AHDS averages about 4.97 nmol/L, roughly twice the upper limit of normal.

The trial reports values in nmol/L, so the molar LOINC code is used. Age-specific paediatric intervals differ; the cohort study assessed T3 against age-specific upper limits rather than a single adult cut-off. ANALYTE MISMATCH FLAG: this marker is TOTAL T3 (LOINC:14930-2), but the abnormal interpretation band below is bound to HP:0011788 "Increased circulating free T3" because HPO has no "increased circulating total T3" term (the HP:0031508 subtree was enumerated and contains no total-T3 equivalent). HP:0011788 is used as the closest available term; a new-term request to HPO for an increased-total-T3 class would resolve this.

Show evidence (2 references)

PMID:31377265 SUPPORT Human Clinical

"the goal of attaining serum total T3 concentrations within the target range of 1·4-2·5 nmol/L"

Source of the 1.4-2.5 nmol/L normal interval adopted as the treatment target in the pivotal Triac trial.

PMID:31377265 SUPPORT Human Clinical

"Serum T3 concentration decreased from 4·97 nmol/L (SD 1·55) at baseline to 1·82 nmol/L (0·69) at month 12"

Documents the untreated AHDS baseline (mean 4.97 nmol/L) that anchors the abnormal bands, and its normalization on Triac.

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"Tri-iodothyronine concentrations were above the age-specific upper limit in 96 (95%) of 101 patients"

Establishes near-universal T3 elevation in genetically confirmed patients.

Serum free thyroxine (free T4) (DECREASED)

Reference Ranges

Thyroxine (T4) free [Moles/volume] in Serum or Plasma 10.0–25.0 pmol/L (Adults; conventional clinical laboratory interval, assay- and age-dependent.)

Low free T4, typical of untreated MCT8 deficiency (–10.0 pmol/L) → Decreased circulating free T4 concentration Normal (10.0–25.0 pmol/L)

Low free T4, typical of untreated MCT8 deficiency: A low free T4 combined with a HIGH T3 is the pattern that distinguishes AHDS. In ordinary primary hypothyroidism both fall together, with a markedly raised TSH.

This interval is a conventional adult clinical laboratory range with no single citable primary source, so it is recorded here rather than attributed to a fabricated citation; individual laboratories and paediatric age bands differ, and the international cohort study assessed free T4 against age-specific lower limits rather than a fixed cut-off. The AHDS-relevant anchor that IS sourced is the trial baseline mean of 9.5 pmol/L.

Show evidence (1 reference)

PMID:31377265 PARTIAL Human Clinical

"serum free T4 concentrations decreased from 9·5 pmol/L (SD 2·5) to 3·4"

Marked PARTIAL because it does not state the reference interval itself; it supplies the untreated AHDS baseline free T4 (mean 9.5 pmol/L) that sits at or below the lower limit, and shows that Triac lowers it further.

Show evidence (1 reference)

PMID:32559475 SUPPORT Human Clinical

"free thyroxine concentrations were below the age-specific lower limit in 94 (89%) of 106 patients"

Establishes low free T4 in 89% of genetically confirmed patients.

Serum thyroid-stimulating hormone (TSH) (NORMAL)

Reference Ranges

Thyrotropin [Units/volume] in Serum or Plasma 0.4–4.0 mU/L (Adults; conventional clinical laboratory interval, assay- and age-dependent.)

Inappropriately normal TSH in the presence of high T3 (0.4–4.0 mU/L) → Inappropriately normal thyroid-stimulating hormone level Mildly elevated TSH (4.0–10.0 mU/L)

Inappropriately normal TSH in the presence of high T3: A numerically normal TSH is the expected AHDS result and must not be read as reassuring. Interpreted against a T3 of roughly twice normal, a TSH in this band is inappropriately non-suppressed and is diagnostically informative.

Mildly elevated TSH: A mild TSH elevation also occurs in AHDS and does not exclude it; it should not be treated with levothyroxine, which worsens the peripheral thyrotoxicosis.

As for free T4, this is a conventional adult clinical laboratory interval with no single citable primary source and is recorded here rather than attributed to a fabricated citation. The sourced AHDS anchor is the trial baseline mean TSH of 2.91 mU/L, which is normal despite grossly elevated T3.

Show evidence (1 reference)

PMID:31377265 PARTIAL Human Clinical

"serum TSH concentrations decreased from 2·91 mU/L (SD 1·68) to 1·02 mU/L"

Marked PARTIAL because it reports the AHDS baseline rather than the reference interval; the baseline mean of 2.91 mU/L demonstrates the inappropriately normal TSH.

Show evidence (1 reference)

clinicaltrials:NCT02060474 SUPPORT Other

"TH serum parameters are highly abnormal in AHDS: high T3, low T4 and normal TSH levels."

States that TSH is normal in AHDS despite the abnormal T3 and T4.

Serum sex hormone-binding globulin (SHBG) (INCREASED)

Show evidence (1 reference)

PMID:34679181 SUPPORT Human Clinical

"SHBG concentrations decreased from 245 (99) to 209 (92) nmol/L (mean decrease 36 nmol/L; 95% CI, 16-57; P = 0.0008)"

Documents the elevated baseline SHBG and its fall on Triac, confirming SHBG as a marker of peripheral thyroid hormone action in AHDS.

Serum reverse T3 (rT3) (DECREASED)

Show evidence (1 reference)

PMID:22993035 SUPPORT Human Clinical

"DITPA normalized the elevated serum T(3) and TSH when the dose reached 1 mg/kg · d and T(4) and rT(3) increased to the lower normal range."

That T4 and rT3 rose INTO the lower normal range on treatment establishes that both were subnormal in untreated AHDS.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Allan-Herndon-Dudley Syndrome:

Resistance to thyroid hormone alpha (THRA) Not Yet Curated MONDO:0034216

Overlapping Features RTH-alpha is the closest biochemical mimic: it also presents with neurodevelopmental impairment and a discordant thyroid profile. It is distinguished by a low or low-normal T4 with a HIGH-NORMAL or only modestly raised T3 and a lower T3/T4 ratio, and by the absence of the marked peripheral thyrotoxic features (resting tachycardia, progressive weight loss, muscle wasting) that dominate AHDS. The lesion is in the receptor (THRA), not the transporter, so hormone reaches cells normally.

Distinguishing Features

AHDS has markedly elevated T3, an elevated T3/T4 ratio, low reverse T3, and prominent tachycardia and failure to thrive. RTH-alpha lacks the peripheral thyrotoxic signature. Definitive separation is by sequencing SLC16A2 versus THRA.

Show evidence (1 reference)

PMID:38963712 SUPPORT Other

"Impaired sensitivity to thyroid hormones encompasses disorders with defective transport of hormones into cells, reduced hormone metabolism, and resistance to hormone action."

The ETA guideline groups transport defects (AHDS) and resistance to hormone action (RTH) as the distinct arms of impaired sensitivity to thyroid hormone that must be separated diagnostically.

Pelizaeus-Merzbacher disease MONDO:0017222

Overlapping Features A leading differential for the hypomyelination seen on MRI. Both present in male infants with hypotonia, nystagmus, and delayed myelination, but PMD is caused by PLP1 dosage abnormalities and has an entirely normal thyroid profile. Checking a T3 in any boy with unexplained hypomyelination is the cheap discriminator.

Distinguishing Features

Normal thyroid function tests in PMD versus the high-T3, low-free-T4, normal-TSH triad in AHDS; PLP1 duplication or point mutation rather than SLC16A2 loss of function.

Cerebral palsy MONDO:0006497

Overlapping Features Because AHDS presents with non-progressive-appearing hypotonia evolving to spastic quadriplegia in a child with normal birth history, it is frequently misdiagnosed as cerebral palsy, which is a major driver of the reported diagnostic delay.

Distinguishing Features

Absence of a perinatal insult, the pathognomonic thyroid profile, and a positive family history on the maternal side favour AHDS.

Show evidence (1 reference)

PMID:39132310 SUPPORT Other

"decreased awareness and recognition of MCT8 deficiency among healthcare professionals (HCPs) associated with misdiagnosis and delays in diagnosis"

Documents misdiagnosis as a recognised problem in MCT8 deficiency, supporting the need to list common mimics explicitly.

🔬

Clinical Trials

3

NCT02060474 PHASE_II COMPLETED

The Triac Trial: an investigator-initiated, international, open-label, single-arm phase 2 trial of oral Triac (tiratricol) in male paediatric and adult patients with MCT8 deficiency, testing whether an MCT8-independent T3 analogue can reduce the toxic effects of high serum T3 and restore local thyroid hormone availability in brain. 46 patients enrolled; serum T3 fell from 4.97 to 1.82 nmol/L at 12 months.

Target Phenotypes: Elevated serum T3 HP:0011788 Failure to thrive / underweight HP:0001508 Resting tachycardia HP:0001649

Show evidence (2 references)

clinicaltrials:NCT02060474 SUPPORT Other

"The current trial will investigate if Triac treatment in ADHS patients 1. reduces the toxic effects of the high T3 levels 2. restores the local TH deficiency in brain."

States the trial's two objectives, mapping onto the two arms of the disease mechanism.

PMID:31377265 SUPPORT Human Clinical

"This trial is registered with ClinicalTrials.gov, number NCT02060474."

Links the published trial report to this NCT registration.

NCT02396459 PHASE_II ACTIVE_NOT_RECRUITING

Triac Trial II: tiratricol treatment of young boys aged 30 months or younger with MCT8 deficiency, designed specifically to test whether starting treatment early enough can benefit the cerebral-hypothyroidism arm, which Triac Trial I did not establish. Initial treatment period is 96 weeks with an optional 3-year extension.

Target Phenotypes: Global delay in myelination HP:0012448 Elevated serum T3 HP:0011788

Show evidence (1 reference)

clinicaltrials:NCT02396459 SUPPORT Other

"The hypothesis tested is that treatment with tiratricol will have a beneficial effect on the hypothyroid state in the brain as well as the hyperthyroid state in peripheral organs and tissues in these patients."

States the dual-arm hypothesis and confirms that cerebral benefit remains an open question under active investigation.

NCT05579327 PHASE_III COMPLETED

ReTRIACt: a double-blind, randomised, placebo-controlled phase 3 withdrawal study in males aged 4 years and over with MCT8 deficiency already stable on tiratricol. Participants were randomised to continue tiratricol or switch to placebo for 30 days or until serum total T3 rose above the upper limit of normal (the rescue criterion). This randomised-withdrawal design is the highest-tier evidence for tiratricol in AHDS, because the earlier Triac trials were single-arm and open-label.

Target Phenotypes: Elevated serum T3 HP:0011788

Show evidence (2 references)

clinicaltrials:NCT05579327 SUPPORT Other

"This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency."

Establishes the phase 3, randomised, placebo-controlled design and the target population.

clinicaltrials:NCT05579327 SUPPORT Other

"The research hypothesis to be tested is that, for participants in the placebo group, removal of tiratricol will lead to an increase of serum total T3 concentration"

States the withdrawal hypothesis, which targets the elevated serum T3 phenotype curated in this entry.

{ }

Source YAML

click to show

name: Allan-Herndon-Dudley Syndrome
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
synonyms:
- MCT8 deficiency
- monocarboxylate transporter 8 deficiency
- MCT8-specific thyroid hormone cell membrane transporter deficiency
- AHDS
description: >-
  An X-linked disorder of thyroid hormone cell-membrane transport caused by
  loss-of-function variants in SLC16A2, which encodes monocarboxylate
  transporter 8 (MCT8). Because MCT8 is the rate-limiting route for
  triiodothyronine (T3) entry across the blood-brain barrier and into
  MCT8-dependent neurons, but is dispensable in liver, heart, and skeletal
  muscle, a single transporter defect produces two opposite hormonal states at
  once: cerebral hypothyroidism (severe intellectual disability, hypotonia
  evolving to spastic quadriplegia, dystonia, absent speech, delayed
  myelination) alongside peripheral thyrotoxicosis (hypermetabolism, failure to
  thrive, muscle wasting, tachycardia). The signature serum pattern is high T3
  with low or low-normal free T4 and a normal or only mildly elevated TSH.
disease_term:
  preferred_term: Allan-Herndon-Dudley syndrome
  term:
    id: MONDO:0010354
    label: Allan-Herndon-Dudley syndrome
parents:
- X-linked intellectual disability
- Thyroid hormone transport defect
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    notes: >-
      AHDS is a genetic disorder of thyroid hormone transport with a
      pathognomonic thyroid function test pattern (high T3, low free T4,
      non-suppressed TSH), placing it in the endocrinology and metabolism
      domain.
  - classification_value: NEUROLOGIC
    notes: >-
      The dominant clinical burden is neurological - severe intellectual
      disability, hypotonia evolving to spastic tetraplegia, extrapyramidal
      movement disorder, and hypomyelination - so the disorder is also curated
      under the neurologic chapter.
notes: >-
  Module conformance is deliberately partial. Only the cerebral arm of AHDS
  declares conforms_to against
  hypothyroidism_thyroid_hormone_deficiency#Reduced Thyroid Hormone Action at
  Peripheral Sites, because that is the one conserved step AHDS genuinely
  reproduces: a target tissue receives an inadequate thyroid hormone stimulus
  and its thyroid-hormone-dependent developmental program fails. AHDS does NOT
  conform to the module's other four nodes, and asserting that it did would be
  wrong. Thyroid hormone synthesis is normal (there is no gland lesion);
  circulating hormone is not deficient (serum T3 is elevated, so the module's
  "Thyroid Hormone Insufficiency" node is inverted); and the systemic state is
  hypermetabolic rather than hypometabolic, inverting both "Decreased Metabolic
  Rate" and "Systemic Hypometabolic State". AHDS is therefore a transport
  defect producing tissue-selective, not systemic, hormone deficiency, and the
  peripheral arm of this entry is the mechanistic opposite of the module.
  This partial fit is the clinically important teaching point and the reason
  levothyroxine replacement fails: it treats the module's chain, not the
  transport lesion.
references:
- reference: PMID:20301789
  title: "Allan-Herndon-Dudley Syndrome."
  tags:
  - GeneReviews
- reference: PMID:38963712
  title: >-
    2024 European Thyroid Association Guidelines on diagnosis and management of
    genetic disorders of thyroid hormone transport, metabolism and action.
- reference: PMID:39132310
  title: >-
    Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a
    review.
inheritance:
- name: X-linked recessive inheritance
  description: >-
    AHDS is inherited in an X-linked manner. Hemizygous males carrying a
    pathogenic SLC16A2 variant are affected. Heterozygous females are usually
    not clinically affected but may show minor thyroid test abnormalities, with
    variability attributable to skewed X-inactivation.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AHDS is inherited in an X-linked manner.
    explanation: GeneReviews states the X-linked mode of inheritance directly.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      females who inherit the variant will be heterozygotes (carriers) and
      usually will not be clinically affected but may have minor thyroid test
      abnormalities
    explanation: >-
      Documents the mild or absent carrier phenotype in heterozygous females,
      consistent with X-linked recessive inheritance modulated by
      X-inactivation.
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Heterozygous females had a milder thyroid phenotype and no neurological
      defects.
    explanation: >-
      The original gene-discovery families showed the same carrier pattern:
      biochemical abnormality without neurological disease in females.
pathophysiology:
- name: SLC16A2 Loss of Function
  description: >-
    Loss-of-function variants in SLC16A2 at Xq13.2 (deletions, nonsense,
    frameshift, and missense variants that misfold or mistraffic the protein)
    abolish or severely reduce the activity of monocarboxylate transporter 8
    (MCT8), a 12-transmembrane-domain thyroid hormone-specific plasma membrane
    transporter. Because males are hemizygous, a single variant allele removes
    all functional transporter.
  role: trigger
  biological_scale: MOLECULAR
  genes:
  - preferred_term: SLC16A2
    term:
      id: hgnc:10923
      label: SLC16A2
  evidence:
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We now report, for the first time, mutations in the monocarboxylate
      transporter 8 (MCT8) gene, located on the X chromosome, that encodes a
      613-amino acid protein with 12 predicted transmembrane domains.
    explanation: >-
      Establishes SLC16A2/MCT8 as the mutated gene and describes the encoded
      12-transmembrane-domain transporter.
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      linkage studies have placed the gene locus in Xq13.2. Mutations in the
      monocarboxylate transporter 8 gene (MCT8) have been found in each of the
      six families.
    explanation: >-
      Confirms that the historically defined Allan-Herndon-Dudley families all
      carry MCT8 mutations at Xq13.2, anchoring disease identity to SLC16A2.
  - reference: PMID:15488219
    reference_title: "Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two patients, gene deletions of 2.4 kb and 24 kb were recorded and in
      three patients missense mutations Ala150Val, Arg171 stop, and Leu397Pro
      were identified.
    explanation: >-
      Documents the allelic spectrum, spanning whole-gene deletions through
      missense substitutions, all producing loss of function.
  downstream:
  - target: MCT8 Thyroid Hormone Transport Failure
    description: >-
      Absence of functional transporter protein directly abolishes
      MCT8-mediated cellular uptake of thyroid hormone.
    causal_link_type: DIRECT
- name: MCT8 Thyroid Hormone Transport Failure
  description: >-
    MCT8 is a thyroid hormone-specific transporter that carries T3 and T4 across
    the plasma membrane. Its loss does not affect hormone synthesis or receptor
    function; it blocks hormone entry into cells. Critically, MCT8 dependence is
    tissue-selective. Brain barriers and many neurons rely on MCT8 as the
    rate-limiting import route, whereas liver, heart, and skeletal muscle import
    T3 through alternative transporters (MCT10, OATP family). This single lesion
    therefore partitions the body into hormone-deprived and
    hormone-overexposed compartments.
  role: central_effector
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: Thyroid Hormone Transport
    term:
      id: GO:0070327
      label: thyroid hormone transport
    modifier: DECREASED
  evidence:
  - reference: PMID:15488219
    reference_title: "Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We suggest that this novel syndrome of X-linked psychomotor retardation is
      due to a defect in T3 entry into neurons through MCT8, resulting in
      impaired T3 action and metabolism.
    explanation: >-
      States the core mechanism: failure of T3 entry into neurons through MCT8
      rather than any defect of hormone production or receptor action.
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One essential function of the protein encoded by this gene appears to be
      the transport of triiodothyronine into neurons.
    explanation: >-
      Identifies neuronal T3 import as the essential MCT8 function that is lost.
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      MCT8 is a thyroid hormone (TH) transporter which is crucial for the
      transport of TH from the blood into different tissues. Dysfunction of MCT8
      results in a lack of TH (hypothyroidism) in tissues that depend on MCT8
      for TH uptake.
    explanation: >-
      States the tissue-selective logic of MCT8 dependence that underlies the
      simultaneous two-compartment phenotype.
  downstream:
  - target: Cerebral Thyroid Hormone Deprivation
    description: >-
      Loss of MCT8-mediated transport across brain barriers and into neurons
      starves the CNS of thyroid hormone.
    causal_link_type: DIRECT
  - target: Signature Serum Iodothyronine Pattern
    description: >-
      Blocked cellular uptake and altered peripheral deiodinase handling shift
      circulating iodothyronines toward high T3 with low free T4.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Cerebral Thyroid Hormone Deprivation
  description: >-
    Brain thyroid hormone content falls despite normal or elevated circulating
    T3, because MCT8 is the rate-limiting import step at the blood-brain barrier
    and in MCT8-dependent neurons. The CNS therefore behaves as a hypothyroid
    tissue: T3-responsive gene programs are under-driven, and compensatory
    deiodinase changes (increased DIO2, decreased DIO3) fail to restore local
    hormone supply. This is the one conserved step AHDS shares with classical
    hypothyroidism, and the only node here that declares module conformance.
  role: central_effector
  biological_scale: TISSUE
  conforms_to: "hypothyroidism_thyroid_hormone_deficiency#Reduced Thyroid Hormone Action at Peripheral Sites"
  biological_processes:
  - preferred_term: Response to Thyroid Hormone
    term:
      id: GO:0097066
      label: response to thyroid hormone
    modifier: DECREASED
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Disordered thyroid hormone transport, due to mutations in the SLC16A2 gene
      encoding monocarboxylate transporter 8 (MCT8), is characterised by
      intellectual and motor disability resulting from cerebral hypothyroidism
      and chronic peripheral thyrotoxicosis.
    explanation: >-
      Names cerebral hypothyroidism as the direct cause of the intellectual and
      motor disability, alongside the simultaneous peripheral thyrotoxicosis.
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This local hypothyroidism in the brain of these patients causes severe
      psychomotor retardation.
    explanation: >-
      States the causal link from local (brain-restricted) hypothyroidism to the
      severe neurodevelopmental phenotype.
  - reference: PMID:17318265
    reference_title: "Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In the mutants' brains, entry of T4 was not affected, but uptake of T3 was
      diminished. Moreover, the T4 and T3 content in the brain of MCT8-null mice
      was decreased, the activity of D2 was increased, and D3 activity was
      decreased, indicating the hypothyroid state of this tissue.
    explanation: >-
      Direct experimental demonstration in Mct8-null mice that brain T3 uptake
      and brain hormone content fall, with the deiodinase shifts that define a
      locally hypothyroid tissue. Mouse evidence; the murine CNS phenotype is
      milder than the human one.
  - reference: PMID:38376950
    reference_title: "Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      MCT8-deficient COs exhibited (i) altered early neurodevelopment, resulting
      in smaller neural rosettes with thinner cortical units, (ii) impaired
      triiodothyronine (T3) transport in developing neural cells, as assessed
      through deiodinase-3-mediated T3 catabolism, (iii) reduced expression of
      genes involved in cerebral cortex development, and (iv) reduced T3
      inducibility of TH-regulated genes.
    explanation: >-
      Patient-derived human cerebral organoids demonstrate the full chain within
      human neural tissue: impaired T3 transport, blunted T3-responsive gene
      induction, and disrupted cortical development. This is the strongest
      human-specific evidence for the cerebral arm and sidesteps the species
      differences that limit mouse models.
  downstream:
  - target: Impaired Oligodendrocyte Maturation and Hypomyelination
    description: >-
      Thyroid hormone is the timing signal for oligodendrocyte precursor
      differentiation; without it, myelination is delayed.
    causal_link_type: DIRECT
  - target: Disrupted Neuronal and Cerebellar Development
    description: >-
      T3-dependent programs governing GABAergic interneuron, cortical, and
      cerebellar maturation are under-driven.
    causal_link_type: DIRECT
- name: Impaired Oligodendrocyte Maturation and Hypomyelination
  description: >-
    Thyroid hormone provides the temporal cue that drives oligodendrocyte
    precursor cells to exit the progenitor state and become mature, myelinating
    oligodendrocytes. In MCT8 deficiency the precursor pool expands while mature
    oligodendrocyte numbers fall, a differentiation block that produces reduced
    myelin content, a shift toward small-caliber myelinated axons, and the
    global delay in myelination seen on MRI in essentially every patient.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: Oligodendrocyte Precursor Cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  biological_processes:
  - preferred_term: Oligodendrocyte Differentiation
    term:
      id: GO:0048709
      label: oligodendrocyte differentiation
    modifier: DECREASED
  - preferred_term: Myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:37307933
    reference_title: "Thyroid hormone transporter Mct8/Oatp1c1 deficiency compromises proper oligodendrocyte maturation in the mouse CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Proper CNS myelination depends on the timed availability of thyroid
      hormone (TH) that induces differentiation of oligodendrocyte precursor
      cells (OPCs) to mature, myelinating oligodendrocytes.
    explanation: >-
      Establishes the thyroid-hormone dependence of the OPC-to-oligodendrocyte
      transition that fails when brain hormone supply is lost.
  - reference: PMID:37307933
    reference_title: "Thyroid hormone transporter Mct8/Oatp1c1 deficiency compromises proper oligodendrocyte maturation in the mouse CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Dko mice exhibited at all analysed time points an increased portion of
      OPCs and a reduced number of mature oligodendrocytes both in white and
      grey matter regions indicating a differentiation blockage in the absence
      of Mct8/Oatp1c1.
    explanation: >-
      Demonstrates the specific cellular lesion, an oligodendrocyte
      differentiation block, in the Mct8/Oatp1c1 double-knockout model of human
      MCT8 deficiency.
  - reference: PMID:34838669
    reference_title: "Deficient thyroid hormone transport to the brain leads to impairments in axonal caliber and oligodendroglial development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the MCT8-deficient subject presents severely reduced myelin lipid and
      protein staining and increased proportion of small-caliber myelinated
      axons in detriment of large-caliber ones
    explanation: >-
      Human post-mortem brain histology confirms that the myelin deficit and
      axonal caliber shift are real features of MCT8-deficient human brain, not
      only of the mouse model.
  downstream:
  - target: Delayed myelination
    description: >-
      The oligodendrocyte differentiation block manifests radiologically as a
      global delay in myelination.
    causal_link_type: DIRECT
  - target: Spastic tetraplegia
    description: >-
      Deficient myelination of corticospinal projections contributes to the
      pyramidal signs that supersede infantile hypotonia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Inability to walk
    description: >-
      Combined hypomyelination of motor pathways and central motor
      under-development leaves most affected males unable to walk independently.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Disrupted Neuronal and Cerebellar Development
  description: >-
    Beyond myelin, thyroid hormone drives neuronal migration, dendritic
    arborization, GABAergic interneuron maturation, and cerebellar granule and
    Purkinje cell development. Loss of brain hormone supply during the critical
    developmental window leaves these programs incomplete and irreversible,
    which is why the few motor and cognitive abilities patients acquire do not
    improve with age.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: GABAergic Interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: Cerebellar Purkinje Cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: Central Nervous System Development
    term:
      id: GO:0007417
      label: central nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The few motor and cognitive abilities of patients did not improve with
      age, as evidenced by the absence of significant correlations between
      biological age and scores on the Gross Motor Function Measure-88 and
      Bayley Scales of Infant Development III.
    explanation: >-
      Documents the fixed, non-progressive developmental ceiling expected from a
      failure of a time-limited developmental program rather than an ongoing
      degenerative process.
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thyroid hormones are iodothyronines that control growth and development,
      as well as brain function and metabolism.
    explanation: >-
      States the developmental role of thyroid hormone in the brain whose
      interruption underlies the neurodevelopmental phenotype.
  - reference: PMID:17318265
    reference_title: "Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: >-
      however, cerebellar Purkinje cells appeared unaffected, since they did not
      exhibit dendritic outgrowth defects and responded normally to T3 treatment
      in vitro
    explanation: >-
      Marked PARTIAL because it qualifies rather than supports the cerebellar
      arm: single Mct8 knockout mice spare Purkinje cell dendritic development,
      which is why the mouse CNS phenotype is milder than the human disease and
      why Mct8/Oatp1c1 double knockouts are the better model.
  downstream:
  - target: Severe intellectual disability
    description: Failure of T3-dependent cortical development produces severe cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Axial hypotonia
    description: >-
      Immature central motor control presents in infancy as truncal hypotonia
      and absent head control.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Dystonia
    description: >-
      Under-development of basal ganglia and interneuron circuits produces
      extrapyramidal movement abnormalities.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Choreoathetosis
    description: Extrapyramidal circuit immaturity also produces choreoathetoid posturing.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Absent speech
    description: Severe global neurodevelopmental failure leaves most patients without speech.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Seizure
    description: >-
      Disrupted excitatory-inhibitory balance from impaired GABAergic
      development predisposes to often drug-resistant seizures.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Feeding difficulties
    description: >-
      Immature bulbar and oromotor control produces infantile feeding
      difficulty and excessive drooling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Dysphagia
    description: >-
      The same bulbar and oromotor deficit impairs swallowing, predisposing to
      aspiration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Aspiration pneumonia
    description: >-
      Aspiration of food and secretions across an incompetent swallow produces
      the pulmonary infection that is the leading cause of death.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Nystagmus
    description: >-
      Immature central oculomotor and cerebellar control produces rotary
      nystagmus and impaired gaze.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Scoliosis
    description: >-
      Truncal hypotonia, spasticity, and absent independent ambulation combine
      to produce neuromuscular scoliosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hip dislocation
    description: >-
      The same abnormal tone and absence of weight-bearing predispose to hip
      dysplasia and dislocation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Signature Serum Iodothyronine Pattern
  description: >-
    The diagnostic biochemical triad is high serum T3 with low or low-normal
    free T4 and a normal or only mildly elevated TSH, giving an increased
    T3/T4 ratio and low reverse T3. This pattern arises because tissues that
    retain hormone uptake (notably liver) increase type 1 deiodinase activity,
    converting T4 to T3, while the pituitary and hypothalamus receive a mixed
    signal, so TSH is not suppressed to the degree the elevated T3 would
    predict. The combination is what distinguishes AHDS from ordinary primary
    hypothyroidism (low T3 and T4 with high TSH) and from thyroid hormone
    resistance syndromes, and it is the diagnostic key.
  role: biomarker
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: Thyroid Hormone Metabolic Process
    term:
      id: GO:0042403
      label: thyroid hormone metabolic process
    modifier: ABNORMAL
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In addition, TH serum parameters are highly abnormal in AHDS: high T3, low
      T4 and normal TSH levels.
    explanation: States the signature triad explicitly.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tri-iodothyronine concentrations were above the age-specific upper limit
      in 96 (95%) of 101 patients and free thyroxine concentrations were below
      the age-specific lower limit in 94 (89%) of 106 patients.
    explanation: >-
      Quantifies the penetrance of the high-T3, low-free-T4 pattern in the
      largest genetically confirmed cohort assembled.
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal transporter function is reflected in elevated free
      triiodothyronine and lowered free thyroxine levels in the blood.
    explanation: Links the serum pattern directly to the transporter defect.
  - reference: PMID:17318265
    reference_title: "Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The MCT8-null mice described here, however, developed without overt
      deficits but also exhibited distorted 3,5,3'-triiodothyronine (T3) and
      thyroxine (T4) serum levels, resulting in increased hepatic activity of
      type 1 deiodinase (D1).
    explanation: >-
      Identifies the increased hepatic type 1 deiodinase activity that mechanistically
      generates the elevated serum T3, and confirms the mouse reproduces the human
      serum pattern even though its CNS phenotype is milder.
  downstream:
  - target: Peripheral Thyrotoxicosis in MCT8-Independent Tissues
    description: >-
      The elevated circulating T3 is freely taken up by tissues that do not
      depend on MCT8, over-stimulating them.
    causal_link_type: DIRECT
  - target: Increased circulating free T3
    description: The serum pattern is measured directly as elevated free and total T3.
    causal_link_type: DIRECT
  - target: Decreased circulating free T4 concentration
    description: Enhanced T4-to-T3 conversion lowers circulating free thyroxine.
    causal_link_type: DIRECT
  - target: Inappropriately normal thyroid-stimulating hormone level
    description: >-
      TSH fails to fall as the elevated T3 would predict, because pituitary
      hormone sensing is itself partly MCT8-dependent.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Increased T3/T4 ratio
    description: The divergence of T3 and T4 raises the T3/T4 ratio, a derived diagnostic index.
    causal_link_type: DIRECT
  - target: Decreased circulating reverse T3 concentration
    description: >-
      The shift of peripheral deiodination away from the inactivating type 3
      pathway lowers circulating reverse T3.
    causal_link_type: DIRECT
- name: Peripheral Thyrotoxicosis in MCT8-Independent Tissues
  description: >-
    Liver, heart, kidney, and skeletal muscle import T3 through MCT10, OATP, and
    other non-MCT8 routes, so they are fully exposed to the elevated circulating
    T3. These tissues are therefore chronically thyrotoxic while the brain is
    hypothyroid. This is the mechanistic reason why levothyroxine or
    liothyronine replacement is harmful in AHDS: extra hormone cannot reach the
    brain but does reach and further over-stimulate the periphery.
  role: effector
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: Response to Thyroid Hormone
    term:
      id: GO:0097066
      label: response to thyroid hormone
    modifier: INCREASED
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The high serum T3 levels cause local hyperthyroidism in tissues that do
      not depend on MCT8 for cellular transport of TH, resulting in a low body
      weight and reduced muscle mass.
    explanation: >-
      States the peripheral-thyrotoxicosis arm and its anthropometric
      consequences, in explicit contrast to the hypothyroid brain.
  - reference: PMID:31377265
    reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This chronic thyrotoxicosis leads to progressive deterioration in
      bodyweight, tachycardia, and muscle wasting, predisposing affected
      individuals to substantial morbidity and mortality.
    explanation: >-
      Establishes chronic peripheral thyrotoxicosis as the driver of the
      systemic morbidity and of excess mortality.
  downstream:
  - target: Hypermetabolism and Muscle Wasting
    description: >-
      Excess T3 action in peripheral tissues raises metabolic rate and drives
      catabolism.
    causal_link_type: DIRECT
- name: Hypermetabolism and Muscle Wasting
  description: >-
    Sustained peripheral T3 excess raises basal metabolic rate, increases
    resting heart rate and systolic blood pressure, elevates sex hormone-binding
    globulin, lowers serum creatinine from reduced muscle mass, and produces a
    progressive negative energy balance that manifests as failure to thrive and
    muscle wasting. Being underweight in early childhood is an independent
    predictor of mortality, so this arm is not merely cosmetic.
  role: consequence
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: Regulation of Metabolic Process
    term:
      id: GO:0019222
      label: regulation of metabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The great majority of affected children cannot walk or talk, and all have
      elevated serum T(3) levels, causing peripheral tissue hypermetabolism and
      inability to maintain weight.
    explanation: >-
      Links elevated serum T3 causally to peripheral hypermetabolism and the
      inability to maintain weight.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients who were underweight during age 1-3 years had an increased risk
      for death compared with patients who were of normal bodyweight at this age
      (HR 4·71, 95% CI 1·26-17·58, p=0·021).
    explanation: >-
      Shows the hypermetabolic-catabolic arm is prognostically important, not
      incidental, which is the rationale for treating peripheral thyrotoxicosis.
  - reference: PMID:34679181
    reference_title: "Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with mutations in thyroid hormone transporter MCT8 have
      developmental delay and chronic thyrotoxicosis associated with being
      underweight and having cardiovascular dysfunction.
    explanation: >-
      Associates chronic thyrotoxicosis with the underweight state and
      cardiovascular dysfunction that define this node.
  downstream:
  - target: Failure to thrive
    description: Negative energy balance from hypermetabolism produces poor weight gain.
    causal_link_type: DIRECT
  - target: Decreased muscle mass
    description: Catabolic T3 excess in skeletal muscle drives muscle wasting.
    causal_link_type: DIRECT
  - target: Tachycardia
    description: Excess T3 action on MCT8-independent cardiac tissue raises resting heart rate.
    causal_link_type: DIRECT
  - target: Premature atrial contractions
    description: >-
      The same unopposed atrial T3 action produces ectopic atrial automaticity
      and premature atrial contractions.
    causal_link_type: DIRECT
  - target: Elevated systolic blood pressure
    description: >-
      Increased cardiac output and reduced systemic vascular resistance from
      peripheral T3 excess raise systolic blood pressure.
    causal_link_type: DIRECT
phenotypes:
- category: Neurologic
  name: Severe intellectual disability
  description: >-
    Cognitive impairment is severe to profound in most affected males, although
    the reported range extends from mild to profound.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Severe intellectual disability
    term:
      id: HP:0010864
      label: Severe intellectual disability
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cognitive development is severely impaired.
    explanation: States the severity of cognitive impairment in the classic AHDS families.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      developmental delay / intellectual disability ranging from mild to
      profound
    explanation: >-
      GeneReviews documents developmental delay and intellectual disability as a
      defining feature, with a range extending to profound.
- category: Neurologic
  name: Axial hypotonia
  description: >-
    Truncal and central hypotonia dominate infancy, with poor head control, and
    later give way to spasticity.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Truncal (axial) hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
    temporality: TRANSIENT
  evidence:
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      neurological abnormalities, including global developmental delay, central
      hypotonia, spastic quadriplegia, dystonic movements, rotary nystagmus, and
      impaired gaze and hearing
    explanation: Lists central hypotonia among the defining neurological abnormalities.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hypotonia and feeding difficulties in infancy
    explanation: GeneReviews establishes infantile hypotonia as a presenting feature.
- category: Neurologic
  name: Spastic tetraplegia
  description: >-
    Infantile hypotonia is replaced over childhood and adult life by pyramidal
    signs and spastic quadriplegia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Spastic quadriplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypotonia gives way in adult life to spasticity.
    explanation: >-
      Documents the characteristic evolution from infantile hypotonia to
      spasticity.
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      central hypotonia, spastic quadriplegia, dystonic movements
    explanation: Names spastic quadriplegia in the original gene-discovery probands.
- category: Neurologic
  name: Dystonia
  description: >-
    Extrapyramidal findings include dystonia, paroxysmal movement disorder,
    hypokinesia, and masked facies.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      extrapyramidal findings (dystonia, choreoathetosis, paroxysmal movement
      disorder, hypokinesia, masked facies)
    explanation: >-
      GeneReviews enumerates the extrapyramidal features, dystonia first among
      them.
- category: Neurologic
  name: Choreoathetosis
  description: >-
    Choreoathetoid movements and dystonic-athetoid posturing of the hands with
    fisting are characteristic.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      extrapyramidal findings (dystonia, choreoathetosis, paroxysmal movement
      disorder, hypokinesia, masked facies)
    explanation: GeneReviews lists choreoathetosis among the extrapyramidal findings.
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The hands exhibit dystonic and athetoid posturing and fisting.
    explanation: Describes the characteristic athetoid hand posturing.
- category: Neurologic
  name: Absent speech
  description: Speech is dysarthric or, more commonly, absent altogether.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Absent or minimal speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Speech is dysarthric or absent altogether.
    explanation: Documents absent or severely dysarthric speech.
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The great majority of affected children cannot walk or talk
    explanation: >-
      Confirms that the great majority of affected children never acquire
      speech.
- category: Neurologic
  name: Inability to walk
  description: >-
    Most affected males never achieve independent ambulation; those who do walk
    are ataxic.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Inability to walk independently
    term:
      id: HP:0002540
      label: Inability to walk
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Generalized weakness is manifested by excessive drooling, forward
      positioning of the head and neck, failure to ambulate independently, or
      ataxia in those who do ambulate.
    explanation: >-
      Documents failure of independent ambulation, with ataxia in the minority
      who walk.
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The great majority of affected children cannot walk or talk
    explanation: Confirms the high frequency of non-ambulation.
- category: Neurologic
  name: Seizure
  description: >-
    Seizures occur in a substantial minority and are often resistant to
    anti-seizure medication.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizures, often drug-resistant
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and seizures, often with drug resistance
    explanation: >-
      GeneReviews identifies seizures with frequent drug resistance as part of
      the clinical spectrum.
- category: Neurologic
  name: Delayed myelination
  description: >-
    A global delay in myelination is the most consistent brain MRI finding, and
    was present in every patient imaged in the international cohort. Myelination
    partially catches up with age in some patients but remains abnormal.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Global delay in myelination
    term:
      id: HP:0012448
      label: Delayed myelination
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most consistent MRI finding was a global delay in myelination, which
      occurred in 13 (100%) of 13 patients.
    explanation: >-
      Directly supports both the finding and the VERY_FREQUENT band (13 of 13
      imaged patients).
- category: Ophthalmologic
  name: Nystagmus
  description: >-
    Rotary nystagmus with impaired gaze was described in the original
    gene-discovery probands and is a recurrent oculomotor feature. It is one of
    the findings AHDS shares with Pelizaeus-Merzbacher disease, the principal
    hypomyelination differential, which is why the thyroid profile rather than
    the eye findings is the discriminator.
  phenotype_term:
    preferred_term: Rotary nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      neurological abnormalities, including global developmental delay, central
      hypotonia, spastic quadriplegia, dystonic movements, rotary nystagmus, and
      impaired gaze and hearing
    explanation: >-
      Names rotary nystagmus among the defining neurological abnormalities of
      the original MCT8-mutant probands. No frequency is stated in any cited
      source, so no frequency band is asserted.
- category: Gastrointestinal
  name: Feeding difficulties
  description: >-
    Feeding difficulty with excessive drooling begins in infancy and contributes
    to the negative energy balance; some patients require gastrostomy feeding.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hypotonia and feeding difficulties in infancy
    explanation: GeneReviews names feeding difficulties as an infantile feature.
- category: Gastrointestinal
  name: Dysphagia
  description: >-
    Impaired swallowing is common and compounds the negative energy balance;
    aspiration is a contributor to the pulmonary infections that are the leading
    cause of death.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Impaired swallowing
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      multidisciplinary team care is vital to optimize the support provided to
      patients and their caregivers
    explanation: >-
      Marked PARTIAL: this review supports the need for multidisciplinary
      (including feeding and nutrition) care, but the retrieved abstract does
      not itself quantify swallowing impairment. The mechanistic link to
      aspiration pneumonia is supported separately by the cohort mortality data.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      32 (21%) of 151 patients died; the main causes of mortality in these
      patients were pulmonary infection
    explanation: >-
      Marked PARTIAL: supports the clinical significance of aspiration-prone
      swallowing (pulmonary infection is the leading cause of death) rather than
      directly quantifying dysphagia frequency.
- category: Respiratory
  name: Aspiration pneumonia
  description: >-
    Impaired swallowing predisposes to aspiration of food and secretions, and
    the resulting pulmonary infection is the leading cause of death in MCT8
    deficiency: 32 (21%) of 151 patients in the international cohort died, with
    pulmonary infection and sudden death the two main causes, and median overall
    survival was 35.0 years. Regular swallowing assessment by speech therapy and
    radiographic swallow study is recommended specifically to mitigate this
    risk.
  phenotype_term:
    preferred_term: Aspiration pneumonia
    term:
      id: HP:0011951
      label: Aspiration pneumonia
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      are at risk of aspiration pneumonia, so swallowing function should be
      regularly assessed via speech therapy and radiographic swallowing studies
    explanation: >-
      States that children with MCT8 deficiency are at risk of aspiration
      pneumonia and that this risk is the rationale for swallowing
      surveillance. No prevalence figure is given, so no frequency band is
      asserted.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      32 (21%) of 151 patients died; the main causes of mortality in these
      patients were pulmonary infection
    explanation: >-
      Establishes pulmonary infection as a leading cause of death in the largest
      genetically confirmed cohort, quantifying the clinical consequence of the
      aspiration risk. It reports cause-of-death share rather than phenotype
      prevalence, so it does not license a frequency band.
- category: Growth
  name: Failure to thrive
  description: >-
    Poor weight gain is driven by peripheral thyrotoxic hypermetabolism
    compounded by feeding difficulty. In the international cohort, 71% of
    patients with anthropometric data were underweight, and being underweight in
    early childhood carried a nearly fivefold increased risk of death.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Failure to thrive / underweight
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      59 (71%) of 83 patients were underweight.
    explanation: >-
      Quantifies the underweight state at 71%, supporting the FREQUENT band
      (30-79%).
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      dysthyroidism (manifest as poor weight gain, reduced muscle mass, and
      variable cold intolerance, sweating, elevated heart rate, and
      irritability)
    explanation: >-
      GeneReviews attributes poor weight gain specifically to the dysthyroid
      (peripheral thyrotoxic) state.
- category: Musculoskeletal
  name: Decreased muscle mass
  description: >-
    Muscular hypoplasia and progressive muscle wasting reflect catabolic T3
    excess in MCT8-independent skeletal muscle.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Reduced muscle mass / muscular hypoplasia
    term:
      id: HP:0003199
      label: Decreased muscle mass
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Infancy and childhood in the Allan-Herndon-Dudley syndrome are marked by
      hypotonia, weakness, reduced muscle mass, and delay of developmental
      milestones.
    explanation: Names reduced muscle mass among the cardinal early features.
  - reference: PMID:31377265
    reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This chronic thyrotoxicosis leads to progressive deterioration in
      bodyweight, tachycardia, and muscle wasting
    explanation: >-
      Attributes the muscle wasting causally to the chronic peripheral
      thyrotoxicosis.
- category: Musculoskeletal
  name: Scoliosis
  description: >-
    Neuromuscular scoliosis develops from the combination of truncal hypotonia,
    spasticity, and absent independent ambulation, and may in turn impede
    respiratory function and sleep. GeneReviews recommends explicit spine
    surveillance for it at every scheduled review.
  phenotype_term:
    preferred_term: Neuromuscular scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      spine for scoliosis and hips for dislocation
    explanation: >-
      GeneReviews names scoliosis as a specific surveillance target in AHDS,
      establishing it as an expected complication. No frequency is reported, so
      no frequency band is asserted.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      patients should be evaluated for scoliosis, which may impede respiratory
      function and sleep
    explanation: >-
      Independently recommends scoliosis evaluation and states its functional
      consequence in MCT8 deficiency.
- category: Musculoskeletal
  name: Hip dislocation
  description: >-
    Hip dysplasia progressing to dislocation is the second orthopaedic
    complication of abnormal tone and absent weight-bearing, is a source of
    discomfort, and is the second explicit GeneReviews surveillance target
    alongside the spine.
  phenotype_term:
    preferred_term: Hip dysplasia and dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      spine for scoliosis and hips for dislocation
    explanation: >-
      GeneReviews names hip dislocation as a specific surveillance target in
      AHDS. No frequency is reported, so no frequency band is asserted.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Orthopedic specialists should be consulted to assess for hip dysplasia,
      which may cause discomfort
    explanation: >-
      Independently recommends orthopaedic assessment for hip dysplasia in MCT8
      deficiency.
- category: Cardiovascular
  name: Tachycardia
  description: >-
    Resting tachycardia, premature atrial contractions, and elevated systolic
    blood pressure reflect unopposed T3 action on the MCT8-independent heart.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Resting tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      25 (53%) of 47 patients had elevated systolic blood pressure above the
      90th percentile, 34 (76%) of 45 patients had premature atrial
      contractions, and 20 (31%) of 64 had resting tachycardia.
    explanation: >-
      Quantifies resting tachycardia at 31%, supporting the FREQUENT band, and
      documents the associated cardiovascular findings.
- category: Cardiovascular
  name: Premature atrial contractions
  description: >-
    Premature atrial contractions are the most frequent cardiovascular finding
    in MCT8 deficiency, recorded in three quarters of patients assessed. They
    reflect chronic unopposed T3 action on the MCT8-independent myocardium and
    are part of the arrhythmic substrate that underlies the sudden deaths
    reported in the international cohort.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Premature atrial contractions
    term:
      id: HP:0006699
      label: Premature atrial contractions
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      34 (76%) of 45 patients had premature atrial contractions
    explanation: >-
      Quantifies premature atrial contractions at 76% of assessed patients,
      which falls in the FREQUENT band (79-30%).
- category: Cardiovascular
  name: Elevated systolic blood pressure
  description: >-
    Systolic blood pressure above the 90th percentile occurs in about half of
    patients assessed and is a further peripheral thyrotoxic cardiovascular
    readout. GeneReviews records that both heart rate and systolic blood
    pressure fall on TRIAC treatment, confirming the causal attribution to
    excess peripheral T3 action.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Systolic blood pressure above the 90th percentile
    term:
      id: HP:0004421
      label: Elevated systolic blood pressure
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      25 (53%) of 47 patients had elevated systolic blood pressure above the
      90th percentile
    explanation: >-
      Quantifies elevated systolic blood pressure at 53% of assessed patients,
      which falls in the FREQUENT band (79-30%).
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      decreased heart rate, systolic blood pressure, and hypertension
    explanation: >-
      GeneReviews reports that systolic blood pressure and hypertension fall on
      TRIAC, confirming that the elevated pressure is driven by the treatable
      peripheral thyrotoxicosis.
- category: Endocrine
  name: Increased circulating free T3
  description: >-
    Elevated serum triiodothyronine is the single most consistent biochemical
    abnormality and the entry point to diagnosis.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Elevated serum T3
    term:
      id: HP:0011788
      label: Increased circulating free T3
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tri-iodothyronine concentrations were above the age-specific upper limit
      in 96 (95%) of 101 patients
    explanation: >-
      Quantifies elevated T3 in 95% of tested patients, supporting the
      VERY_FREQUENT band.
- category: Endocrine
  name: Decreased circulating free T4 concentration
  description: >-
    Free thyroxine is low or low-normal, the counterintuitive counterpart of the
    elevated T3 and the reason the pattern is diagnostically distinctive.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Low or low-normal free T4
    term:
      id: HP:0033078
      label: Decreased circulating free T4 concentration
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      free thyroxine concentrations were below the age-specific lower limit in
      94 (89%) of 106 patients
    explanation: >-
      Quantifies low free T4 in 89% of tested patients, supporting the
      VERY_FREQUENT band.
- category: Endocrine
  name: Inappropriately normal thyroid-stimulating hormone level
  description: >-
    TSH is normal or only mildly elevated despite the markedly elevated T3 that
    would ordinarily suppress it. This inappropriate normality completes the
    diagnostic triad and separates AHDS from primary hypothyroidism and from
    thyrotoxicosis of thyroidal origin.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Normal or only mildly elevated TSH despite high T3
    term:
      id: HP:0033075
      label: Inappropriately normal thyroid-stimulating hormone level
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TH serum parameters are highly abnormal in AHDS: high T3, low T4 and
      normal TSH levels.
    explanation: >-
      States the normal TSH in the presence of high T3, the third element of the
      diagnostic triad.
- category: Endocrine
  name: Increased T3/T4 ratio
  description: >-
    The divergence of T3 and T4 raises the T3/T4 ratio, a derived index that is
    more discriminating than either hormone alone.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Elevated T3/T4 ratio
    term:
      id: HP:0012559
      label: Increased T3/T4 ratio
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal transporter function is reflected in elevated free
      triiodothyronine and lowered free thyroxine levels in the blood.
    explanation: >-
      The simultaneous elevation of T3 and reduction of T4 described here is
      exactly what an increased T3/T4 ratio measures.
- category: Endocrine
  name: Decreased circulating reverse T3 concentration
  description: >-
    Reverse T3 is low, reflecting the shift of peripheral deiodination toward
    activating (type 1 and type 2) rather than inactivating (type 3) pathways.
    Its diagnostic importance is disproportionate to its obscurity: it is the
    only characteristic MCT8-related thyroid hormone alteration already present
    in the newborn period, before the pathognomonic rise in T3 appears at around
    four months of age.
  diagnostic: true
  phenotype_term:
    preferred_term: Low reverse T3
    term:
      id: HP:6001334
      label: Decreased circulating reverse T3 concentration
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The only characteristic MCT8-related thyroid hormone alteration that is
      present within the newborn period is a low reverse T3 (rT3)
    explanation: >-
      Establishes the low reverse T3 as a characteristic MCT8-deficiency
      alteration and the only one detectable in the newborn period. No
      prevalence figure is given, so no frequency band is asserted.
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DITPA normalized the elevated serum T(3) and TSH when the dose reached 1
      mg/kg · d and T(4) and rT(3) increased to the lower normal range.
    explanation: >-
      That reverse T3 rose INTO the lower normal range on treatment establishes
      that it was subnormal in untreated AHDS.
biochemical:
- name: Serum total triiodothyronine (T3)
  notes: >-
    Serum T3 is elevated in essentially all affected males and is the entry
    point to the diagnosis. In the Triac Trial cohort, mean baseline T3 was
    4.97 nmol/L against a normal target range of 1.4-2.5 nmol/L, roughly double
    the upper limit of normal.
  presence: INCREASED
  reference_ranges:
  - loinc_term:
      id: LOINC:14930-2
      label: Triiodothyronine (T3) [Moles/volume] in Serum or Plasma
    lower_bound: 1.4
    upper_bound: 2.5
    unit: nmol/L
    population: >-
      Reference target range used in the international Triac Trial for
      paediatric and adult males with MCT8 deficiency.
    evidence:
    - reference: PMID:31377265
      reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the goal of attaining serum total T3 concentrations within the target
        range of 1·4-2·5 nmol/L
      explanation: >-
        Source of the 1.4-2.5 nmol/L normal interval adopted as the treatment
        target in the pivotal Triac trial.
    - reference: PMID:31377265
      reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Serum T3 concentration decreased from 4·97 nmol/L (SD 1·55) at baseline
        to 1·82 nmol/L (0·69) at month 12
      explanation: >-
        Documents the untreated AHDS baseline (mean 4.97 nmol/L) that anchors
        the abnormal bands, and its normalization on Triac.
    notes: >-
      The trial reports values in nmol/L, so the molar LOINC code is used.
      Age-specific paediatric intervals differ; the cohort study assessed T3
      against age-specific upper limits rather than a single adult cut-off.
      ANALYTE MISMATCH FLAG: this marker is TOTAL T3 (LOINC:14930-2), but the
      abnormal interpretation band below is bound to HP:0011788 "Increased
      circulating free T3" because HPO has no "increased circulating total T3"
      term (the HP:0031508 subtree was enumerated and contains no total-T3
      equivalent). HP:0011788 is used as the closest available term; a new-term
      request to HPO for an increased-total-T3 class would resolve this.
    interpretation_bands:
    - name: Normal
      lower_bound: 1.4
      upper_bound: 2.5
      unit: nmol/L
      abnormal_flag: NORMAL
      interpretation: >-
        Within the target range used in the Triac trials. Untreated AHDS
        essentially never falls here; a normal T3 on treatment is the
        therapeutic goal.
    - name: Elevated T3 typical of untreated MCT8 deficiency
      lower_bound: 2.5
      unit: nmol/L
      abnormal_flag: HIGH
      phenotype_term:
        preferred_term: Elevated serum T3
        term:
          id: HP:0011788
          label: Increased circulating free T3
      interpretation: >-
        An elevated T3 in a boy with severe developmental delay and hypotonia
        should prompt free T4, TSH, and SLC16A2 sequencing. Untreated AHDS
        averages about 4.97 nmol/L, roughly twice the upper limit of normal.
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tri-iodothyronine concentrations were above the age-specific upper limit
      in 96 (95%) of 101 patients
    explanation: Establishes near-universal T3 elevation in genetically confirmed patients.
- name: Serum free thyroxine (free T4)
  notes: >-
    Free T4 is low or low-normal, the opposite direction to T3. Mean baseline
    free T4 in the Triac Trial cohort was 9.5 pmol/L, at or below the lower end
    of the usual adult interval.
  presence: DECREASED
  reference_ranges:
  - loinc_term:
      id: LOINC:14920-3
      label: Thyroxine (T4) free [Moles/volume] in Serum or Plasma
    lower_bound: 10.0
    upper_bound: 25.0
    unit: pmol/L
    population: >-
      Adults; conventional clinical laboratory interval, assay- and
      age-dependent.
    notes: >-
      This interval is a conventional adult clinical laboratory range with no
      single citable primary source, so it is recorded here rather than
      attributed to a fabricated citation; individual laboratories and
      paediatric age bands differ, and the international cohort study assessed
      free T4 against age-specific lower limits rather than a fixed cut-off. The
      AHDS-relevant anchor that IS sourced is the trial baseline mean of
      9.5 pmol/L.
    evidence:
    - reference: PMID:31377265
      reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        serum free T4 concentrations decreased from 9·5 pmol/L (SD 2·5) to 3·4
      explanation: >-
        Marked PARTIAL because it does not state the reference interval itself;
        it supplies the untreated AHDS baseline free T4 (mean 9.5 pmol/L) that
        sits at or below the lower limit, and shows that Triac lowers it
        further.
    interpretation_bands:
    - name: Low free T4, typical of untreated MCT8 deficiency
      upper_bound: 10.0
      unit: pmol/L
      abnormal_flag: LOW
      phenotype_term:
        preferred_term: Low or low-normal free T4
        term:
          id: HP:0033078
          label: Decreased circulating free T4 concentration
      interpretation: >-
        A low free T4 combined with a HIGH T3 is the pattern that distinguishes
        AHDS. In ordinary primary hypothyroidism both fall together, with a
        markedly raised TSH.
    - name: Normal
      lower_bound: 10.0
      upper_bound: 25.0
      unit: pmol/L
      abnormal_flag: NORMAL
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      free thyroxine concentrations were below the age-specific lower limit in
      94 (89%) of 106 patients
    explanation: Establishes low free T4 in 89% of genetically confirmed patients.
- name: Serum thyroid-stimulating hormone (TSH)
  notes: >-
    TSH is normal or only mildly elevated, which is inappropriate for the
    markedly elevated T3. Mean baseline TSH in the Triac Trial cohort was
    2.91 mU/L, squarely within the normal interval despite a T3 roughly twice
    the upper limit of normal. This non-suppression is the third leg of the
    triad and reflects partial MCT8 dependence of hypothalamic-pituitary
    hormone sensing.
  presence: NORMAL
  reference_ranges:
  - loinc_term:
      id: LOINC:3016-3
      label: Thyrotropin [Units/volume] in Serum or Plasma
    lower_bound: 0.4
    upper_bound: 4.0
    unit: mU/L
    population: Adults; conventional clinical laboratory interval, assay- and age-dependent.
    notes: >-
      As for free T4, this is a conventional adult clinical laboratory interval
      with no single citable primary source and is recorded here rather than
      attributed to a fabricated citation. The sourced AHDS anchor is the trial
      baseline mean TSH of 2.91 mU/L, which is normal despite grossly elevated
      T3.
    evidence:
    - reference: PMID:31377265
      reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        serum TSH concentrations decreased from 2·91 mU/L (SD 1·68) to 1·02
        mU/L
      explanation: >-
        Marked PARTIAL because it reports the AHDS baseline rather than the
        reference interval; the baseline mean of 2.91 mU/L demonstrates the
        inappropriately normal TSH.
    interpretation_bands:
    - name: Inappropriately normal TSH in the presence of high T3
      lower_bound: 0.4
      upper_bound: 4.0
      unit: mU/L
      abnormal_flag: NORMAL
      phenotype_term:
        preferred_term: Normal or only mildly elevated TSH despite high T3
        term:
          id: HP:0033075
          label: Inappropriately normal thyroid-stimulating hormone level
      interpretation: >-
        A numerically normal TSH is the expected AHDS result and must not be
        read as reassuring. Interpreted against a T3 of roughly twice normal, a
        TSH in this band is inappropriately non-suppressed and is diagnostically
        informative.
    - name: Mildly elevated TSH
      lower_bound: 4.0
      upper_bound: 10.0
      unit: mU/L
      abnormal_flag: HIGH
      severity: MILD
      interpretation: >-
        A mild TSH elevation also occurs in AHDS and does not exclude it; it
        should not be treated with levothyroxine, which worsens the peripheral
        thyrotoxicosis.
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TH serum parameters are highly abnormal in AHDS: high T3, low T4 and
      normal TSH levels.
    explanation: States that TSH is normal in AHDS despite the abnormal T3 and T4.
- name: Serum sex hormone-binding globulin (SHBG)
  notes: >-
    SHBG is a hepatic marker of T3 action. Because the liver is
    MCT8-independent and therefore thyrotoxic, SHBG is elevated in AHDS and
    falls when peripheral thyrotoxicosis is treated, making it a useful
    peripheral-tissue readout of thyroid hormone action.
  presence: INCREASED
  evidence:
  - reference: PMID:34679181
    reference_title: "Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SHBG concentrations decreased from 245 (99) to 209 (92) nmol/L (mean
      decrease 36 nmol/L; 95% CI, 16-57; P = 0.0008)
    explanation: >-
      Documents the elevated baseline SHBG and its fall on Triac, confirming
      SHBG as a marker of peripheral thyroid hormone action in AHDS.
- name: Serum reverse T3 (rT3)
  notes: >-
    Reverse T3 is low in AHDS, consistent with the shift of peripheral
    deiodination toward activating (type 1 and type 2) rather than inactivating
    (type 3) pathways.
  presence: DECREASED
  evidence:
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DITPA normalized the elevated serum T(3) and TSH when the dose reached 1
      mg/kg · d and T(4) and rT(3) increased to the lower normal range.
    explanation: >-
      That T4 and rT3 rose INTO the lower normal range on treatment establishes
      that both were subnormal in untreated AHDS.
genetic:
- name: SLC16A2
  association: Loss-of-function variants
  relationship_type: CAUSATIVE
  notes: >-
    SLC16A2 (MCT8) at Xq13.2 encodes a thyroid hormone-specific plasma membrane
    transporter. Pathogenic variants span whole-gene and partial deletions,
    nonsense and frameshift variants, and missense variants that impair
    trafficking or transport. Genotype-phenotype correlation is imperfect, but
    variants retaining partial residual transport activity are associated with
    milder presentations.
  gene_term:
    preferred_term: SLC16A2
    term:
      id: hgnc:10923
      label: SLC16A2
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Six large families with the syndrome have been identified, and linkage
      studies have placed the gene locus in Xq13.2. Mutations in the
      monocarboxylate transporter 8 gene (MCT8) have been found in each of the
      six families.
    explanation: >-
      Establishes SLC16A2/MCT8 at Xq13.2 as the cause in every historically
      defined Allan-Herndon-Dudley family.
  - reference: PMID:14661163
    reference_title: "A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings establish the physiological importance of MCT8 as a thyroid
      hormone transporter.
    explanation: Original gene-discovery paper establishing MCT8 as the disease gene.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we enrolled 151 patients with 73 different MCT8 (SLC16A2) mutations
    explanation: >-
      Demonstrates the wide allelic heterogeneity, with 73 distinct variants
      across 151 genetically confirmed patients.
  - reference: PMID:15488219
    reference_title: "Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two patients, gene deletions of 2.4 kb and 24 kb were recorded and in
      three patients missense mutations Ala150Val, Arg171 stop, and Leu397Pro
      were identified.
    explanation: >-
      Documents the variant classes asserted in the notes - whole-gene and
      partial deletions, nonsense, and missense substitutions - in the original
      cohort.
  - reference: PMID:27977298
    reference_title: "The Chemical Chaperone Phenylbutyrate Rescues MCT8 Mutations Associated With Milder Phenotypes in Patients With Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Some MCT8-deficient patients (e.g., those carrying MCT8delF501) will not
      be as severely affected as most others. We have shown that the MCT8delF501
      protein has decreased protein stability but important residual function
      once it reaches the plasma membrane.
    explanation: >-
      Sources the genotype-phenotype statement in the notes: variants retaining
      residual transport function are associated with milder presentations. Also
      identifies the misfolding/destabilisation variant class that is rescuable
      by chemical chaperones in vitro.
  - reference: PMID:27977298
    reference_title: "The Chemical Chaperone Phenylbutyrate Rescues MCT8 Mutations Associated With Milder Phenotypes in Patients With Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Kinetic analyses revealed that the Michaelis constants of the mutants
      toward the primary substrate 3,3',5-triiodothyronine were not much
      different from the wild-type value, suggesting that these mutants are not
      impaired in their interaction with substrate but rather destabilized by
      the mutation and degraded.
    explanation: >-
      Establishes the molecular basis of the milder missense class: normal
      substrate affinity with reduced protein stability, rather than an
      intrinsically dead transporter.
treatments:
- name: Tiratricol (Triac)
  description: >-
    Triac (3,3',5-triiodothyroacetic acid, tiratricol) is a T3 analogue that
    binds the same thyroid hormone receptors as T3 but enters cells
    independently of MCT8. It is the rational therapy for AHDS: it suppresses
    the pituitary, lowering the elevated serum T3 and thereby relieving
    peripheral thyrotoxicosis, and can in principle reach MCT8-dependent tissues
    that T3 cannot. In the international phase 2 Triac Trial (46 patients),
    serum T3 fell from 4.97 to 1.82 nmol/L over 12 months with only transient
    adverse effects; a real-life cohort of 67 patients treated up to 6 years
    confirmed sustained benefit with gains in body weight, reductions in heart
    rate, and falling SHBG. Evidence that Triac reverses the cerebral
    hypothyroidism is much weaker than the evidence for peripheral benefit, and
    is the question Triac Trial II was designed to answer by treating boys aged
    30 months or younger.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tiratricol
      term:
        id: CHEBI:40021
        label: tiratricol
  target_mechanisms:
  - target: Peripheral Thyrotoxicosis in MCT8-Independent Tissues
    treatment_effect: INHIBITS
    description: >-
      By suppressing TSH and lowering circulating T3, Triac removes the excess
      hormone driving MCT8-independent tissues, which is the arm of the disease
      it demonstrably improves.
  - target: Cerebral Thyroid Hormone Deprivation
    treatment_effect: INHIBITS
    description: >-
      Triac enters cells without MCT8 and can therefore in principle substitute
      for T3 in MCT8-dependent brain tissue. This is the therapeutic rationale
      but remains the less well demonstrated of the two effects.
  target_phenotypes:
  - preferred_term: Elevated serum T3
    term:
      id: HP:0011788
      label: Increased circulating free T3
  - preferred_term: Failure to thrive / underweight
    term:
      id: HP:0001508
      label: Failure to thrive
  - preferred_term: Resting tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Cellular uptake of Triac does not depend on functional MCT8.
    explanation: >-
      States the pharmacological property that makes Triac rational in a
      transport-defect disease.
  - reference: PMID:31377265
    reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Key features of peripheral thyrotoxicosis were alleviated in paediatric
      and adult patients with MCT8 deficiency who were treated with Triac. Triac
      seems a reasonable treatment strategy to ameliorate the consequences of
      untreated peripheral thyrotoxicosis in patients with MCT8 deficiency.
    explanation: >-
      Primary trial conclusion: Triac alleviates peripheral thyrotoxicosis. Note
      the deliberately limited claim, confined to the peripheral arm.
  - reference: PMID:34679181
    reference_title: "Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Key features were sustainably alleviated in patients with MCT8 deficiency
      across all ages, highlighting the real-life potential of Triac for MCT8
      deficiency.
    explanation: >-
      Long-term real-life cohort confirming durability of benefit over up to six
      years.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main objective, normalization of the free T3 blood level, was
      achieved. Other favorable findings were increased body weight; decreased
      heart rate, systolic blood pressure, and hypertension; and improved
      development in seven children
    explanation: >-
      GeneReviews summary of the Triac evidence, including the developmental
      signal in a small subgroup of early-treated children.
  - reference: PMID:38376950
    reference_title: "Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, the TH analogs 3,5-diiodothyropropionic acid and
      3,3',5-triiodothyroacetic acid triggered normal responses
      (induction/repression of T3-responsive genes) in MCT8-deficient COs,
      constituting proof of concept that lack of T3 transport underlies the
      pathophysiology of AHDS and demonstrating the clinical potential for TH
      analogs to be used in treating patients with AHDS.
    explanation: >-
      Human patient-derived cerebral organoids show that Triac (and DITPA)
      restore normal T3-responsive gene regulation where T3 itself cannot,
      giving direct human-tissue proof of concept for the MCT8-bypass strategy
      in the brain.
- name: Diiodothyropropionic acid (DITPA)
  description: >-
    DITPA is a second MCT8-independent thyroid hormone analogue. In four
    children treated on compassionate grounds for 26-40 months, DITPA
    normalized elevated serum T3 and TSH, raised T4 and reverse T3 into the low
    normal range, and reduced SHBG and heart rate without adverse effects.
    Evidence is far more limited than for Triac and DITPA is not in routine use,
    but it establishes that the MCT8-bypass strategy generalizes beyond a single
    compound.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: diiodothyropropionic acid
      term:
        id: CHEBI:134267
        label: 3,5-diiodothyropropionic acid
  target_mechanisms:
  - target: Peripheral Thyrotoxicosis in MCT8-Independent Tissues
    treatment_effect: INHIBITS
    description: >-
      DITPA lowers circulating T3 and reduces markers of peripheral
      hypermetabolism such as SHBG and heart rate.
  evidence:
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DITPA (1-2 mg/kg · d) almost completely normalizes thyroid tests and
      reduces the hypermetabolism and the tendency for weight loss.
    explanation: >-
      Conclusion of the compassionate-use series in four children, supporting
      DITPA as an alternative MCT8-independent analogue.
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In Mct8-deficient mice, the thyroid hormone analog, diiodothyropropionic
      acid (DITPA), does not require MCT8 to enter tissues and could be an
      effective alternative to thyroid hormone treatment in humans.
    explanation: >-
      States the preclinical MCT8-independence rationale established in
      Mct8-deficient mice.
- name: Thyroid hormone replacement (levothyroxine or liothyronine) - contraindicated as monotherapy
  description: >-
    Standard thyroid hormone replacement fails in AHDS and is harmful.
    Levothyroxine or liothyronine cannot cross into MCT8-dependent brain
    tissue, so the cerebral hypothyroidism is not corrected, while the
    additional hormone is fully available to MCT8-independent peripheral tissues
    and therefore aggravates the existing thyrotoxicosis and hypermetabolism.
    GeneReviews lists administration of L-T4 or L-T3 alone under agents and
    circumstances to avoid. This is the single most important management point
    in the disease and the reason the correct diagnosis matters: a boy with
    developmental delay and a low free T4 will otherwise be given levothyroxine.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levothyroxine
      term:
        id: CHEBI:30660
        label: thyroxine
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Agents/circumstances to avoid: Administration of L-T4 or L-T3 alone can
      exacerbate the high serum T3 levels and the resulting hypermetabolism.
    explanation: >-
      GeneReviews drug-safety warning naming L-T4 and L-T3 monotherapy as agents
      to avoid.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thyroid hormone replacement therapy during childhood has no beneficial
      effect and could be dangerous by worsening dysthyroidism.
    explanation: >-
      States both the lack of benefit and the potential harm of conventional
      replacement.
  - reference: PMID:22993035
    reference_title: "Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment with thyroid hormone is ineffective.
    explanation: Independent confirmation that conventional thyroid hormone is ineffective.
- name: Multidisciplinary supportive and rehabilitative care
  description: >-
    There is no disease-modifying therapy for the neurological phenotype, so
    management is supportive: physiotherapy and positioning for hypotonia and
    spasticity, management of extrapyramidal movement disorders, nutritional
    support (including gastrostomy where feeding difficulty and weight loss
    demand it), and surveillance for scoliosis and hip dislocation.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Multidisciplinary team to provide standard care for hypotonia, poor
      feeding, DD/ID, spasticity, and extrapyramidal movement disorders.
    explanation: GeneReviews management recommendation for multidisciplinary supportive care.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surveillance: In children, assess the following every six months until age
      four years, then once a year: developmental progress & educational needs;
      neurologic examination for new manifestations
    explanation: Documents the recommended surveillance schedule.
- name: Anti-seizure medication
  description: >-
    Seizures are managed with standard anti-seizure medication under an
    experienced neurologist, but drug resistance is common.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Anticonvulsant Therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
  target_phenotypes:
  - preferred_term: Seizures, often drug-resistant
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Standard treatment with anti-seizure medication by an experienced
      neurologist.
    explanation: GeneReviews management recommendation for the seizure phenotype.
- name: Genetic counseling and carrier testing
  description: >-
    Because AHDS is X-linked, carrier testing of at-risk female relatives,
    prenatal testing, and preimplantation genetic testing become available once
    the familial SLC16A2 variant is known. A carrier mother has a 50% chance of
    transmitting the variant in each pregnancy.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the SLC16A2 pathogenic variant has been identified in an affected
      family member, carrier testing of at-risk female relatives, prenatal
      testing for a pregnancy at increased risk, and preimplantation genetic
      testing are possible.
    explanation: GeneReviews genetic counseling guidance.
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If the mother of a proband has an SLC16A2 pathogenic variant, the chance
      of transmitting it in each pregnancy is 50%.
    explanation: >-
      GeneReviews states the 50% per-pregnancy transmission risk verbatim,
      sourcing the figure asserted in this treatment description.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      there is a 50% chance that male children will be affected if their mother
      is a carrier of a pathogenic SLC16A2 mutation
    explanation: >-
      Independently states the sex-specific consequence of the 50% transmission
      risk in this X-linked disorder.
clinical_trials:
- name: NCT02060474
  phase: PHASE_II
  status: COMPLETED
  description: >-
    The Triac Trial: an investigator-initiated, international, open-label,
    single-arm phase 2 trial of oral Triac (tiratricol) in male paediatric and
    adult patients with MCT8 deficiency, testing whether an MCT8-independent T3
    analogue can reduce the toxic effects of high serum T3 and restore local
    thyroid hormone availability in brain. 46 patients enrolled; serum T3 fell
    from 4.97 to 1.82 nmol/L at 12 months.
  target_phenotypes:
  - preferred_term: Elevated serum T3
    term:
      id: HP:0011788
      label: Increased circulating free T3
  - preferred_term: Failure to thrive / underweight
    term:
      id: HP:0001508
      label: Failure to thrive
  - preferred_term: Resting tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: clinicaltrials:NCT02060474
    reference_title: "Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The current trial will investigate if Triac treatment in ADHS patients

      1. reduces the toxic effects of the high T3 levels
      2. restores the local TH deficiency in brain.
    explanation: >-
      States the trial's two objectives, mapping onto the two arms of the
      disease mechanism.
  - reference: PMID:31377265
    reference_title: "Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This trial is registered with ClinicalTrials.gov, number NCT02060474.
    explanation: Links the published trial report to this NCT registration.
- name: NCT02396459
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Triac Trial II: tiratricol treatment of young boys aged 30 months or younger
    with MCT8 deficiency, designed specifically to test whether starting
    treatment early enough can benefit the cerebral-hypothyroidism arm, which
    Triac Trial I did not establish. Initial treatment period is 96 weeks with
    an optional 3-year extension.
  target_phenotypes:
  - preferred_term: Global delay in myelination
    term:
      id: HP:0012448
      label: Delayed myelination
  - preferred_term: Elevated serum T3
    term:
      id: HP:0011788
      label: Increased circulating free T3
  evidence:
  - reference: clinicaltrials:NCT02396459
    reference_title: "Tiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial II"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The hypothesis tested is that treatment with tiratricol will have a
      beneficial effect on the hypothyroid state in the brain as well as the
      hyperthyroid state in peripheral organs and tissues in these patients.
    explanation: >-
      States the dual-arm hypothesis and confirms that cerebral benefit remains
      an open question under active investigation.
- name: NCT05579327
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ReTRIACt: a double-blind, randomised, placebo-controlled phase 3
    withdrawal study in males aged 4 years and over with MCT8 deficiency already
    stable on tiratricol. Participants were randomised to continue tiratricol or
    switch to placebo for 30 days or until serum total T3 rose above the upper
    limit of normal (the rescue criterion). This randomised-withdrawal design is
    the highest-tier evidence for tiratricol in AHDS, because the earlier Triac
    trials were single-arm and open-label.
  target_phenotypes:
  - preferred_term: Elevated serum T3
    term:
      id: HP:0011788
      label: Increased circulating free T3
  evidence:
  - reference: clinicaltrials:NCT05579327
    reference_title: "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This is a double-blind, randomized phase 3 multicenter placebo-controlled
      study in at least 16 evaluable male participants diagnosed with MCT8
      deficiency.
    explanation: >-
      Establishes the phase 3, randomised, placebo-controlled design and the
      target population.
  - reference: clinicaltrials:NCT05579327
    reference_title: "Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The research hypothesis to be tested is that, for participants in the
      placebo group, removal of tiratricol will lead to an increase of serum
      total T3 concentration
    explanation: >-
      States the withdrawal hypothesis, which targets the elevated serum T3
      phenotype curated in this entry.
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  notes: >-
    AHDS is a rare X-linked disorder. Systematic prevalence estimates are not
    available; the largest genetically confirmed series assembled 151 patients
    from 47 hospitals across 22 countries over 17 years, which is the best
    available proxy for rarity. The prevalence_class is therefore an inference
    from cohort size and geographic spread rather than a measured rate, and no
    rate_per_100000 is asserted.
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Between Oct 14, 2014, and Jan 17, 2020, we enrolled 151 patients with 73
      different MCT8 (SLC16A2) mutations.
    explanation: >-
      Marked PARTIAL because the study reports a case series, not a population
      prevalence. It bounds rarity: an international 22-country effort over
      years assembled only 151 genetically confirmed patients.
progression:
- phase: Infancy
  notes: >-
    Presentation is with truncal hypotonia, poor head control, and feeding
    difficulties, usually in the first year. Median age at diagnosis in the
    international cohort was 24 months.
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Median age at diagnosis was 24·0 months (IQR 12·0-60·0, range 0·0-744·0).
    explanation: Documents the typical age at diagnosis and its wide range.
- phase: Childhood and adult life
  notes: >-
    Hypotonia is superseded by pyramidal signs and spastic quadriplegia;
    extrapyramidal features and, in some, seizures emerge. Cognitive and motor
    abilities plateau and do not improve with age. Progressive weight loss and
    muscle wasting from chronic peripheral thyrotoxicosis dominate systemic
    morbidity.
  evidence:
  - reference: PMID:15889350
    reference_title: "Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypotonia gives way in adult life to spasticity.
    explanation: Documents the hypotonia-to-spasticity transition over the disease course.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The few motor and cognitive abilities of patients did not improve with
      age
    explanation: Documents the developmental plateau.
- phase: Survival
  notes: >-
    Median overall survival is 35 years. About one in five patients died in the
    international cohort, most commonly from pulmonary infection or sudden
    death. Failure to attain head control by 18 months and being underweight at
    ages 1-3 years are both independent predictors of mortality, which is the
    prognostic argument for treating the peripheral thyrotoxic arm.
  evidence:
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Median overall survival was 35·0 years (95% CI 8·3-61·7).
    explanation: Provides the median overall survival in the largest cohort assembled.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      32 (21%) of 151 patients died; the main causes of mortality in these
      patients were pulmonary infection
    explanation: Provides the mortality rate and the leading cause of death.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals who did not attain head control by age 1·5 years had an
      increased risk of death compared with patients who did attain head control
    explanation: Documents failure of head control as an independent mortality predictor.
diagnosis:
- name: Serum thyroid function testing (T3, free T4, TSH)
  description: >-
    The diagnostic entry point is a serum thyroid panel that INCLUDES T3. After
    about four months of age the profile is a characteristic fingerprint:
    elevated free or total T3, low or low-normal free T4, and a normal or only
    slightly elevated TSH. Because T3 is not part of routine paediatric thyroid
    testing, the single most common obstacle to diagnosis outside the newborn
    period is simply that serum T3 is never measured. Only resistance to thyroid
    hormone alpha produces a similar pattern, so the biochemistry narrows the
    differential to two disorders before any sequencing is done.
  diagnosis_term:
    preferred_term: thyroid function testing
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    Elevated T3 with low or low-normal free T4 and a normal or mildly elevated
    TSH, giving an increased T3/T4 ratio. An elevated T3 in a boy with
    unexplained developmental delay should trigger confirmatory SLC16A2
    sequencing.
  markers: T3, free T4, TSH, T3/T4 ratio, reverse T3, SHBG
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      elevated T3 with low FT4 and normal or slightly elevated TSH
    explanation: >-
      States the characteristic thyroid hormone profile on which the clinical
      diagnosis rests.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Outside of the newborn period, the most common obstacle to diagnosis is
      the infrequent assessment of serum T3
    explanation: >-
      Identifies failure to measure serum T3 as the dominant cause of diagnostic
      delay, which is why this test is listed first.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tri-iodothyronine concentrations were above the age-specific upper limit
      in 96 (95%) of 101 patients and free thyroxine concentrations were below
      the age-specific lower limit in 94 (89%) of 106 patients.
    explanation: >-
      Quantifies the sensitivity of the biochemical pattern in the largest
      genetically confirmed cohort, and shows the comparison must be against
      age-specific limits.
  - reference: PMID:38963712
    reference_title: "2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      challenges include ruling out other causes of biochemical discordance
    explanation: >-
      The 2024 ETA guideline frames the diagnostic task as excluding other
      causes of discordant thyroid function tests before attributing the pattern
      to a transport defect.
- name: Molecular genetic testing of SLC16A2
  description: >-
    Molecular confirmation is required. In a male proband with suggestive
    findings the diagnosis is established by a hemizygous SLC16A2 pathogenic
    variant; in a female proband by a heterozygous variant. Testing may be
    gene-targeted (single-gene testing or a multigene panel) or comprehensive
    (exome or genome sequencing); when a panel or comprehensive test is ordered
    it is essential to verify that SLC16A2 is actually sequenced and reported.
    Because the variant spectrum is still expanding, previously non-diagnostic
    sequencing should be periodically reanalysed.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  results: >-
    A hemizygous (male) or heterozygous (female) pathogenic SLC16A2 variant
    establishes the diagnosis.
  evidence:
  - reference: PMID:20301789
    reference_title: "Allan-Herndon-Dudley Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of AHDS is established in a male proband with suggestive
      findings and a hemizygous SLC16A2 pathogenic variant identified by
      molecular genetic testing, and in a female proband by identification of a
      heterozygous pathogenic variant in SLC16A2.
    explanation: >-
      GeneReviews DIAGNOSIS/TESTING statement defining how the diagnosis is
      established in each sex.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The strategy for genetic testing can be gene-targeted (single-gene testing
      or multigene panels, including custom-designed panels) or comprehensive
      (whole exome sequencing, exome array, or whole genome sequencing)
    explanation: Documents the tiered testing strategy.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      sequencing test results that previously did not lead to a diagnosis should
      be periodically reanalyzed and updated to provide accurate diagnoses
    explanation: >-
      Supports periodic reanalysis of non-diagnostic sequencing, which matters
      because the SLC16A2 variant spectrum is still growing.
  - reference: PMID:38963712
    reference_title: "2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      making a diagnosis using clinical features together with the
      identification of pathogenic variants in causal genes
    explanation: >-
      The 2024 ETA guideline states that diagnosis of these disorders combines
      clinical features with identification of a pathogenic variant in the
      causal gene.
- name: Brain MRI for myelination
  description: >-
    Brain MRI complements the biochemistry. Children under five years show
    diffusely abnormal white matter indicating severely delayed myelination or
    hypomyelination, most marked in the deep anterior white matter; a global
    delay in myelination was present in every patient imaged in the
    international cohort. Myelination improves partially with age, so a
    near-normal MRI in an older patient does not exclude the diagnosis.
  diagnosis_term:
    preferred_term: brain magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: >-
    Diffusely abnormal white matter with delayed myelination or hypomyelination,
    partially improving with age.
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      neurological evaluation with MRI to assess brain myelination may be
      informative
    explanation: Recommends brain MRI as part of the diagnostic evaluation.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      have shown diffusely abnormal white matter indicative of severely delayed
      myelination or hypomyelination, particularly in the deep anterior white
      matter
    explanation: Describes the expected MRI appearance and its distribution.
  - reference: PMID:32559475
    reference_title: "Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most consistent MRI finding was a global delay in myelination, which
      occurred in 13 (100%) of 13 patients.
    explanation: >-
      Quantifies the consistency of the MRI finding in the genetically confirmed
      cohort.
- name: Reverse T3 in the newborn period
  description: >-
    AHDS is missed by newborn screening. Current TSH/T4-based screening exists
    to detect congenital hypothyroidism and does not measure T3, and newborns
    with MCT8 deficiency have TSH and T4 that are normal for gestational age
    because the pathognomonic T3 rise does not appear until roughly four months
    of age. Adding T3 to the screening panel would not by itself separate MCT8
    deficiency from other thyroid disorders. The only characteristic alteration
    present in the newborn period is a low reverse T3, but this assay is not
    widely available and is rarely performed - a recognised screening gap rather
    than a current recommendation.
  diagnosis_term:
    preferred_term: reverse T3 measurement
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  results: >-
    A low reverse T3 is the only characteristic MCT8-related alteration
    detectable in the newborn period.
  notes: >-
    Recorded as a diagnostic gap, not an established pathway: no newborn
    screening programme currently detects AHDS, and reverse T3 assays are not
    routinely available.
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Current newborn screening (NBS) was established to help identify
      congenital hypothyroidism and does not include serum T3 levels
    explanation: >-
      States why standard newborn screening cannot detect MCT8 deficiency.
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The only characteristic MCT8-related thyroid hormone alteration that is
      present within the newborn period is a low reverse T3 (rT3), however, this
      test may not be readily available and is infrequently performed
    explanation: >-
      Identifies reverse T3 as the only neonatal-period marker and states the
      practical barrier to using it.
differential_diagnoses:
- name: Resistance to thyroid hormone alpha (THRA)
  description: >-
    RTH-alpha is the closest biochemical mimic: it also presents with
    neurodevelopmental impairment and a discordant thyroid profile. It is
    distinguished by a low or low-normal T4 with a HIGH-NORMAL or only modestly
    raised T3 and a lower T3/T4 ratio, and by the absence of the marked
    peripheral thyrotoxic features (resting tachycardia, progressive weight
    loss, muscle wasting) that dominate AHDS. The lesion is in the receptor
    (THRA), not the transporter, so hormone reaches cells normally.
  disease_term:
    preferred_term: resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha
    term:
      id: MONDO:0034216
      label: resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha
  distinguishing_features:
  - >-
      AHDS has markedly elevated T3, an elevated T3/T4 ratio, low reverse T3, and
      prominent tachycardia and failure to thrive. RTH-alpha lacks the peripheral
      thyrotoxic signature. Definitive separation is by sequencing SLC16A2 versus
      THRA.
  evidence:
  - reference: PMID:38963712
    reference_title: "2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Impaired sensitivity to thyroid hormones encompasses disorders with
      defective transport of hormones into cells, reduced hormone metabolism,
      and resistance to hormone action.
    explanation: >-
      The ETA guideline groups transport defects (AHDS) and resistance to
      hormone action (RTH) as the distinct arms of impaired sensitivity to
      thyroid hormone that must be separated diagnostically.
- name: Pelizaeus-Merzbacher disease
  description: >-
    A leading differential for the hypomyelination seen on MRI. Both present in
    male infants with hypotonia, nystagmus, and delayed myelination, but PMD is
    caused by PLP1 dosage abnormalities and has an entirely normal thyroid
    profile. Checking a T3 in any boy with unexplained hypomyelination is the
    cheap discriminator.
  disease_term:
    preferred_term: Pelizaeus-Merzbacher disease, classic form
    term:
      id: MONDO:0017222
      label: Pelizaeus-Merzbacher disease, classic form
  distinguishing_features:
  - >-
      Normal thyroid function tests in PMD versus the high-T3, low-free-T4,
      normal-TSH triad in AHDS; PLP1 duplication or point mutation rather than
      SLC16A2 loss of function.
  notes: >-
    Suggested by the deep-research report as a key differential. No PMID-quotable
    head-to-head comparison was located, so no evidence item is asserted here;
    the distinction rests on the thyroid profile documented elsewhere in this
    entry.
- name: Cerebral palsy
  description: >-
    Because AHDS presents with non-progressive-appearing hypotonia evolving to
    spastic quadriplegia in a child with normal birth history, it is frequently
    misdiagnosed as cerebral palsy, which is a major driver of the reported
    diagnostic delay.
  disease_term:
    preferred_term: cerebral palsy
    term:
      id: MONDO:0006497
      label: cerebral palsy
  distinguishing_features:
  - >-
      Absence of a perinatal insult, the pathognomonic thyroid profile, and a
      positive family history on the maternal side favour AHDS.
  evidence:
  - reference: PMID:39132310
    reference_title: "Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      decreased awareness and recognition of MCT8 deficiency among healthcare
      professionals (HCPs) associated with misdiagnosis and delays in diagnosis
    explanation: >-
      Documents misdiagnosis as a recognised problem in MCT8 deficiency,
      supporting the need to list common mimics explicitly.
discussions:
- discussion_id: ahds-mouse-model-mismatch
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - Cerebral Thyroid Hormone Deprivation
  prompt: >-
    Does the Mct8 single-knockout mouse model the human cerebral phenotype of
    AHDS closely enough for its neurological readouts to be translated, given
    that it reproduces the human serum thyroid profile but develops without
    overt neurological deficits?
  rationale: >-
    This is a genuine translational mismatch rather than a gap in evidence.
    Mct8-null mice reproduce the human biochemical signature almost exactly
    (high T3, low T4, increased hepatic D1) and show reduced brain T3 uptake and
    a locally hypothyroid brain, yet they are neurologically near-normal and
    their cerebellar Purkinje cells develop normally. The accepted explanation
    is species difference in brain thyroid hormone transporter redundancy: mice
    express OATP1C1 at the blood-brain barrier as an alternative T4 route that
    humans rely on much less. Consequently the Mct8/Oatp1c1 double knockout, not
    the single knockout, is the appropriate model, and human iPSC-derived
    cerebral organoids are the strongest human-specific system. Any mouse-derived
    conclusion about the severity, reversibility, or therapeutic window of the
    human cerebral phenotype must be qualified accordingly.
  proposed_experiments:
  - experiment_id: ahds-cross-model-cerebral-deficit
    name: Cross-model comparison of the cerebral deficit
    description: >-
      Compare T3-responsive gene induction, oligodendrocyte maturation, and
      cortical unit thickness across Mct8 single-knockout mouse, Mct8/Oatp1c1
      double-knockout mouse, and patient-derived human cerebral organoids under
      matched analogue treatment, to quantify how much of the human deficit each
      model captures.
    decision_criterion: >-
      If the double-knockout mouse and human organoid converge on comparable
      deficits while the single knockout does not, the single knockout should be
      retired as a model of the human cerebral phenotype.
  - experiment_id: ahds-organoid-therapeutic-window
    name: Therapeutic window mapping in human cerebral organoids
    description: >-
      Apply Triac or DITPA to patient-derived cerebral organoids at staged
      developmental time points to define how late the MCT8-bypass strategy can
      still restore T3-responsive gene programs and cortical unit thickness.
    decision_criterion: >-
      Identification of a developmental stage after which analogue treatment no
      longer restores T3-responsive gene induction would define the human
      therapeutic window and set the target age for early treatment.
  evidence:
  - reference: PMID:17318265
    reference_title: "Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In conclusion, the circulating thyroid hormone levels of MCT8-null mice
      closely resemble those of humans with MCT8 mutations, yet in the mice, CNS
      development is only partially affected.
    explanation: >-
      States the mismatch explicitly: the mouse reproduces the human serum
      pattern but not the human CNS phenotype.
  - reference: PMID:38376950
    reference_title: "Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Given species differences in brain TH transporters and the limitations of
      studies in mice, we generated cerebral organoids (COs) using human induced
      pluripotent stem cells (iPSCs) from MCT8-deficient patients.
    explanation: >-
      Names species differences in brain thyroid hormone transporters and the
      limitations of mouse studies as the explicit motivation for building a
      human model, confirming the mismatch is recognised in the field.

📚

References & Deep Research

References

3

PMID:20301789

Allan-Herndon-Dudley Syndrome.

No top-level findings curated for this source.

PMID:38963712

2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action.

No top-level findings curated for this source.

PMID:39132310

Unmet patient needs in monocarboxylate transporter 8 (MCT8) deficiency: a review.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Allan–Herndon–Dudley Syndrome (MCT8 Deficiency): Comprehensive Disease-Characteristics Report

Edison Scientific Literature 37 citations 2026-07-31T17:55:59.643036

Allan–Herndon–Dudley Syndrome (MCT8 Deficiency): Comprehensive Disease-Characteristics Report

Scope and evidence cutoff. This report emphasizes authoritative guidance and literature available through 2024, supplemented by current ClinicalTrials.gov records retrieved for this review. Evidence labels distinguish human cohorts, guidelines, trials, postmortem studies, animal models, and in-vitro systems. Because AHDS is ultra-rare, many management recommendations rest on observational cohorts, uncontrolled trials, and expert consensus rather than randomized outcome trials.

Executive summary

Allan–Herndon–Dudley syndrome (AHDS), increasingly termed monocarboxylate transporter 8 deficiency (MCT8 deficiency), is an X-linked Mendelian neurodevelopmental and endocrine disorder caused by pathogenic loss-of-function variants in SLC16A2. Defective MCT8 prevents adequate thyroid-hormone transport across brain barriers and into selected neural cells, producing severe developmental cerebral hypothyroidism. At the same time, elevated circulating T3 produces peripheral thyrotoxicosis, malnutrition, muscle wasting, and cardiovascular abnormalities. The characteristic biochemical pattern is high T3, low or low-normal T4, low reverse T3, and normal or mildly elevated TSH. (grijotamartinez2020mct8deficiencythe pages 1-2, persani20242024europeanthyroid pages 5-6)

The largest natural-history data indicate profound motor and cognitive disability, frequent dysphagia and underweight, and median survival of approximately 35 years. Early underweight and failure to acquire head control predict higher childhood mortality. Tiratricol/TRIAC is the most advanced targeted treatment and is strongly recommended in the 2024 European Thyroid Association (ETA) guideline to control peripheral thyrotoxicosis; however, no human regimen has yet definitively rescued the neurocognitive phenotype. The critical therapeutic window probably begins prenatally and declines during the first three years. (geest2021monocarboxylatetransporter8 pages 6-7, persani20242024europeanthyroid pages 13-14, bauer2024unmetpatientneeds pages 6-7)

A compact, knowledge-base-oriented summary follows.

Domain	Curated finding	Quantitative evidence	Suggested ontology/identifier	Evidence type
Disease identity	Allan-Herndon-Dudley syndrome, also termed MCT8 deficiency, is an ultra-rare disorder of thyroid hormone transport caused by SLC16A2 dysfunction (OpenTargets Search: Allan-Herndon-Dudley syndrome-SLC16A2, geest2021monocarboxylatetransporter8 pages 1-2)	Open Targets disease-target score 0.853; ~320 clinical cases described worldwide in reviews (vancamp2020monocarboxylatetransporter8 pages 1-2)	MONDO:0010354; OMIM:300523; MeSH:C537047; SLC16A2	Aggregated disease resource + review
Synonyms	Common synonyms include Allan-Herndon-Dudley syndrome, AHDS, MCT8 deficiency, monocarboxylate transporter 8 deficiency (bauer2024unmetpatientneeds pages 1-2, geest2021monocarboxylatetransporter8 pages 1-2)	—	MONDO:0010354; OMIM:300523	Review/guideline
Etiology	Caused by pathogenic loss-of-function variants in SLC16A2 encoding monocarboxylate transporter 8 (MCT8), a thyroid hormone transporter (grijotamartinez2020mct8deficiencythe pages 1-2, geest2021monocarboxylatetransporter8 pages 1-2)	~150 pathogenic variants reported; ~250 families in one review (moran2022geneticdisordersof pages 4-5, geest2021monocarboxylatetransporter8 pages 5-6)	SLC16A2; MCT8	Human genetics + review
Inheritance	Usually X-linked, predominantly affecting males; rare affected females occur with skewed X-inactivation or chromosomal rearrangements (moran2022geneticdisordersof pages 4-5, bauer2024unmetpatientneeds pages 5-6)	A carrier mother has a 50% risk of transmitting the mutant allele to sons; skewed X-inactivation described in rare females (bauer2024unmetpatientneeds pages 5-6)	X-linked inheritance; SLC16A2	Human clinical/genetic counseling review
Variant spectrum	Variant classes include large deletions, truncating/frameshift/nonsense variants, and missense variants; pathogenicity of many missense variants requires functional testing (geest2021monocarboxylatetransporter8 pages 5-6, persani20242024europeanthyroid pages 5-6)	C-terminal missense variants beyond Met574 may be better tolerated in some cases (geest2021monocarboxylatetransporter8 pages 10-11)	SLC16A2	Human genetics + functional in vitro
Core mechanism	Loss of MCT8 reduces T3/T4 transport across brain barriers and into neural cells, causing cerebral hypothyroidism with simultaneous peripheral thyrotoxicosis from elevated circulating T3 (grijotamartinez2020mct8deficiencythe pages 1-2, geest2021monocarboxylatetransporter8 pages 4-5)	Postmortem human cortex showed ~50% reduction in cerebral T3/T4 in cited review summary (geest2021monocarboxylatetransporter8 pages 4-5, salaslucia2024impairedt3uptake pages 1-2)	SLC16A2; HP:0001252 Hypotonia; HP:0001290 Generalized hypotonia	Human postmortem + model + review
Laboratory signature	Characteristic thyroid hormone “fingerprint”: high T3, low/low-normal T4, low reverse T3, TSH normal or mildly elevated; elevated T3/rT3 ratio is especially characteristic (persani20242024europeanthyroid pages 5-6, bauer2024unmetpatientneeds pages 3-5)	Elevated T3 in 95%; low free T4 in 89%; low total T4 in 90%; low rT3 in 91%; TSH within age-specific range in 89% (geest2021monocarboxylatetransporter8 pages 5-6)	HP:0031508 Increased circulating triiodothyronine level; HP:0011787 Decreased circulating thyroxine level	Human cohort + guideline
Neonatal laboratory pattern	Standard newborn screening usually misses the disorder because T3 is not yet elevated in the neonatal period; low rT3 may be an earlier clue (bauer2024unmetpatientneeds pages 7-8, bauer2024unmetpatientneeds pages 3-5)	In 8 patients with T4-based newborn screening data, 88% had total T4 below the 20th percentile, but none were identified by newborn screening (geest2021monocarboxylatetransporter8 pages 5-6)	Newborn screening limitation; SLC16A2	Human cohort + review
Major neurologic phenotype	Severe intellectual and motor disability with hypotonia, spasticity, dystonia, poor head control, lack of speech, and often inability to sit/walk (geest2021monocarboxylatetransporter8 pages 5-6, persani20242024europeanthyroid pages 13-14)	In a 24-patient cohort: hypotonia 100%, spasticity 71%, dystonia 75%, MRI hypomyelination 19/24; in a larger cohort only 4/77 developed walking abilities (geest2021monocarboxylatetransporter8 pages 5-6, geest2021monocarboxylatetransporter8 pages 6-7)	HP:0001252 Hypotonia; HP:0001257 Spasticity; HP:0001332 Dystonia; HP:0001263 Global developmental delay	Human cohort
Seizures and movement phenomena	Seizures occur in a minority; exaggerated startle/paroxysmal nonepileptic events and choreiform/dystonic manifestations are recognized (moran2022geneticdisordersof pages 4-5, bauer2024unmetpatientneeds pages 3-5)	Seizures in ~25% in review summary; exaggerated startle/paroxysmal nonepileptic events in 11 patients in one movement-disorder summary (moran2022geneticdisordersof pages 4-5, bauer2024unmetpatientneeds pages 3-5)	HP:0001250 Seizure; HP:0001336 Myoclonus (if present); HP:0001332 Dystonia	Human cohort/review
MRI/myelin phenotype	Brain MRI often shows delayed myelination/hypomyelination, especially in early childhood, with uncertainty over delayed versus permanent hypomyelination (vancamp2020monocarboxylatetransporter8 pages 1-2, bauer2024unmetpatientneeds pages 5-6)	Majority of patients abnormal in infancy; 19/24 with hypomyelination in one cohort (geest2021monocarboxylatetransporter8 pages 5-6)	HP:0002188 Delayed CNS myelination	Human MRI cohort + review
Peripheral/nutritional phenotype	Low body weight, muscle wasting/hypotrophic musculature, feeding problems, reflux, constipation, and swallowing impairment reflect peripheral thyrotoxicosis plus neurologic disability (persani20242024europeanthyroid pages 13-14, bauer2024unmetpatientneeds pages 5-6)	Underweight in 71%; hypotrophic musculature in 84%; impaired swallowing in 71% in the international cohort (geest2021monocarboxylatetransporter8 pages 5-6)	HP:0004325 Decreased body weight; HP:0002015 Dysphagia; HP:0002020 Gastroesophageal reflux	Human cohort
Cardiovascular phenotype	Tachycardia, PACs/arrhythmia, systolic hypertension, and conduction abnormalities are common and clinically important (persani20242024europeanthyroid pages 13-14, geest2021monocarboxylatetransporter8 pages 6-7)	Resting tachycardia 31%; elevated systolic blood pressure 53%; premature atrial contractions 76% (geest2021monocarboxylatetransporter8 pages 6-7)	HP:0001649 Tachycardia; HP:0011675 Arrhythmia; HP:0000822 Hypertension	Human cohort
Skeletal/orthopedic phenotype	Scoliosis, hip subluxation, osteoporosis, and later spasticity contribute substantially to disability (persani20242024europeanthyroid pages 13-14, bauer2024unmetpatientneeds pages 5-6)	Quantitative prevalence not consistently reported in retrieved sources	HP:0002650 Scoliosis; HP:0002827 Hip dislocation; HP:0000939 Osteoporosis	Guideline + review
Onset and course	Symptoms usually become apparent after 2–4 months of age; developmental abilities plateau far below age expectations and disease is lifelong/progressive in disability burden (bauer2024unmetpatientneeds pages 3-5, geest2021monocarboxylatetransporter8 pages 6-7)	First symptoms around 4 months; median age at diagnosis 24 months (IQR 12.0–60.0); median delay from symptoms to diagnosis 18 months (IQR 7.8–63.0) (moran2022geneticdisordersof pages 4-5, bauer2024unmetpatientneeds pages 3-5)	Congenital/pediatric neurodevelopmental disorder; HP:0001263	Human cohort + review
Prognosis	Life expectancy is substantially reduced, with childhood deaths often related to pulmonary infection/aspiration and possibly sudden cardiac death (moran2022geneticdisordersof pages 4-5, geest2021monocarboxylatetransporter8 pages 6-7)	Median survival 35 years; ~30% mortality in childhood in review summary; approximately 50% of severely affected patients may die in childhood (moran2022geneticdisordersof pages 4-5, geest2021monocarboxylatetransporter8 pages 6-7)	OMIM:300523	Human cohort + review
Mortality predictors	Early underweight and absent head control are major markers of poor prognosis (geest2021monocarboxylatetransporter8 pages 1-2, geest2021monocarboxylatetransporter8 pages 6-7)	Both linked to higher mortality; being underweight at 1–3 years and no head control before 1.5 years strongly associated with early death (geest2021monocarboxylatetransporter8 pages 6-7)	HP:0004325 Decreased body weight; HP:0001252 Hypotonia	Human cohort
Diagnosis	Diagnostic workup combines clinical phenotype, thyroid profile, MRI, and confirmatory SLC16A2 sequencing; VUS assessment should include segregation, functional assays, and structural modeling (persani20242024europeanthyroid pages 5-6, bauer2024unmetpatientneeds pages 3-5)	2024 ETA recommends sequencing in any male with major biochemical criteria plus developmental delay, hypomyelination, movement disorder, primitive reflexes, or family history (persani20242024europeanthyroid pages 5-6)	SLC16A2 sequencing; MONDO:0010354	Guideline
Differential diagnosis	Key differentials include cerebral palsy, Pelizaeus-Merzbacher(-like) disease, MECP2 duplication, mitochondrial disease, and RTHα; tachycardia/failure to thrive favor MCT8 deficiency over RTHα (bauer2024unmetpatientneeds pages 3-5)	RTHα is the closest biochemical mimic among thyroid disorders in retrieved review table (bauer2024unmetpatientneeds pages 3-5)	THRA; MECP2	Review
Genetic counseling/prevention	Cascade testing, carrier testing for at-risk female relatives, prenatal diagnosis, and preimplantation genetic testing are feasible once a family variant is known (persani20242024europeanthyroid pages 5-6, bauer2024unmetpatientneeds pages 7-8)	Prenatal SLC16A2 testing recommended/considered for at-risk male fetuses in positive families (persani20242024europeanthyroid pages 5-6)	SLC16A2; prenatal testing	Guideline + review
Supportive care	Multidisciplinary care is essential: neurology, endocrinology, gastroenterology/nutrition, cardiology, physical/speech/occupational therapy, orthopedics, and social work/case management (bauer2024unmetpatientneeds pages 5-6, persani20242024europeanthyroid pages 13-14)	In one registry survey only 19% had a pediatric gastroenterologist, 31% had dietary advice, 12.5% of those with feeding problems had a feeding tube, and 1 in 5 lacked regular physical therapy (bauer2024unmetpatientneeds pages 5-6)	NCIT supportive care terms not assigned here; HP:0011968 Feeding difficulties	Registry/review
Tiratricol/TRIAC evidence	TRIAC is the leading targeted therapy; it enters cells independently of MCT8 and improves peripheral thyrotoxicosis, with possible greater neurodevelopmental benefit if started very early (persani20242024europeanthyroid pages 5-6, bauer2024unmetpatientneeds pages 6-7)	Phase 2 Triac Trial I: 46 enrolled, 45 with follow-up, 40 completed 12 months; long-term cohort n=67 (27 trial + 40 compassionate use), 90% achieved target T3 range; improvements in weight, heart rate/rhythm, blood pressure, SHBG/creatinine markers (bauer2024unmetpatientneeds pages 6-7, NCT02060474 chunk 2)	Tiratricol / TRIAC / 3,3',5-triiodothyroacetic acid	Human clinical trial + real-world follow-up
Tiratricol status and current implementation	2024 ETA recommends TRIAC (strong recommendation); expanded access and ongoing early-life/withdrawal studies support real-world implementation (persani20242024europeanthyroid pages 5-6, NCT05911399 chunk 1, NCT05579327 chunk 1, NCT02396459 chunk 1)	Target serum T3 1.4–2.5 nmol/L; Triac Trial II enrolled 22 children ≤30 months; ReTRIACt phase 3 completed with actual enrollment 20; US expanded access posted 2023-06-22 (persani20242024europeanthyroid pages 5-6, NCT05579327 chunk 1, NCT02396459 chunk 1)	NCT02396459; NCT05579327; NCT05911399	Guideline + ClinicalTrials.gov
DITPA evidence	DITPA lowers serum T3/TSH and can cross the BBB independently of MCT8, but published human neurologic benefit has been limited (geest2021monocarboxylatetransporter8 pages 7-9, bauer2024unmetpatientneeds pages 6-7)	Compassionate use in 4 children normalized T3 and TSH but no clear neurocognitive improvement; median treatment 38.5 months (range 26–40) in one review summary (geest2021monocarboxylatetransporter8 pages 7-9)	DITPA / 3,5-diiodothyropropionic acid	Human compassionate use + preclinical
LT4/PTU and conventional thyroid therapy	Postnatal levothyroxine monotherapy is not recommended; LT4+PTU can reduce peripheral thyrotoxicosis but not neurologic deficits and PTU has important toxicity risks (persani20242024europeanthyroid pages 5-6, geest2021monocarboxylatetransporter8 pages 6-7)	LT4+PTU reported in 5 patients; PTU carries severe hepatotoxicity/agranulocytosis risk (geest2021monocarboxylatetransporter8 pages 6-7, bauer2024unmetpatientneeds pages 5-6)	Levothyroxine; propylthiouracil	Human case series + guideline
Chemical chaperone approach	Sodium/glycerol phenylbutyrate aims to rescue selected misfolded MCT8 mutants by improving membrane trafficking; human efficacy remains unproven (bauer2024unmetpatientneeds pages 7-8, NCT05019417 chunk 1)	Prospective GPB trial planned for up to 6 genetically confirmed patients (NCT05019417) (NCT05019417 chunk 1)	NCT05019417	Preclinical + trial registration
Gene therapy	AAV-mediated SLC16A2/Mct8 delivery is a promising preclinical strategy, especially targeting BBB/endothelium, but remains preclinical (bauer2024unmetpatientneeds pages 7-8, maitykumar2022validationofmct8oatp1c1 pages 8-9)	IV AAV9-hMCT8 and AAV-BR1-Mct8 increased brain T3 in mice; no human trial identified in retrieved sources (bauer2024unmetpatientneeds pages 7-8)	SLC16A2 gene therapy	Preclinical animal
Principal animal model	Mct8/Oatp1c1 double-knockout mouse best recapitulates human disease, unlike Mct8 single knockout which lacks the full cerebral phenotype (maitykumar2022validationofmct8oatp1c1 pages 1-2, geest2021monocarboxylatetransporter8 pages 7-9)	dKO mice show decreased life expectancy, central hypothyroidism, peripheral hyperthyroidism, impaired myelination, impaired motor abilities, and peripheral tissue thyrotoxicosis (maitykumar2022validationofmct8oatp1c1 pages 1-2)	Mct8/Oatp1c1 dKO mouse	Animal model
Additional models	Zebrafish and patient-derived iPSC/cerebral organoid systems are useful for mechanism and therapeutic screening (geest2021monocarboxylatetransporter8 pages 7-9, salaslucia2024impairedt3uptake pages 1-2)	TRIAC completely rescued myelination in mct8-/- zebrafish larvae in review summary; human organoids showed D3 activity ~18.4 ± 7.7 vs 5.3 ± 3.1 pmol/mg/h in MCT8-deficient COs (~30% of WT) (geest2021monocarboxylatetransporter8 pages 7-9, salaslucia2024impairedt3uptake pages 4-5)	Zebrafish mct8-/-; iPSC cerebral organoid	Animal + human in vitro
Advanced human model insight	2024 cerebral organoids directly showed impaired T3 uptake/action, smaller rosettes, thinner cortical units, and rescue of T3-responsive genes by DITPA/TRIAC (salaslucia2024impairedt3uptake pages 1-2, salaslucia2024impairedt3uptake pages 4-5)	MCT8-deficient CO D3 activity 5.3 ± 3.1 pmol/mg/h vs control 18.4 ± 7.7; selective MCT8 inhibitor reduced WT D3 activity to 4.4 ± 3.0 (salaslucia2024impairedt3uptake pages 4-5)	Human iPSC-derived cerebral organoid	Human in vitro
Quality-of-life and caregiver burden	Disease burden is high for patients and families; caregiver QoL/economic-burden study has been completed but results were not retrieved here (NCT06060197 chunk 1, bauer2024unmetpatientneeds pages 8-9)	Caregiver study enrolled 21 participants across multiple countries (NCT06060197 chunk 1)	NCT06060197	Observational study/registry

Table: This table condenses high-confidence disease facts for Allan-Herndon-Dudley syndrome/MCT8 deficiency, including identifiers, molecular cause, clinical signature, prognosis, diagnostics, therapies, and key research models. It is designed for rapid knowledge-base curation with quantitative evidence and cited evidence types.

1. Disease information

Definition and identifiers

AHDS is a syndromic X-linked intellectual-developmental disorder caused by deficient cellular thyroid-hormone transport. “MCT8 deficiency” is now preferred in some clinical literature because it identifies the molecular defect and avoids an eponym. (geest2021monocarboxylatetransporter8 pages 1-2, geest2021monocarboxylatetransporter8 pages 5-6)

MONDO: MONDO:0010354.
OMIM: #300523.
MeSH: C537047, Allan-Herndon-Dudley syndrome.
Causal target: SLC16A2, Ensembl ENSG00000147100; Open Targets recognizes one strongly associated target, with an association score of approximately 0.853. (OpenTargets Search: Allan-Herndon-Dudley syndrome-SLC16A2)
Common synonyms: Allan–Herndon–Dudley syndrome; AHDS; MCT8 deficiency; monocarboxylate transporter 8 deficiency; thyroid-hormone transporter defect.
Orphanet/ICD: A specific ORPHA identifier and dedicated ICD-10/ICD-11 code were not established from the retrieved primary evidence. In routine coding, broader rare genetic neurodevelopmental or thyroid-hormone transport categories may therefore be used; these should not be treated as disease-specific identifiers without local verification.

The information summarized here is aggregated disease-level evidence, principally multicenter cohorts, guidelines, reviews, trial registries, and experimental studies—not individual EHR-derived data. Individual case reports contribute to rare presentations and prenatal-treatment observations.

2. Etiology, risk, protection, and environment

Causal factor

The primary and sufficient cause is a germline pathogenic variant in SLC16A2, located at Xq13.2 and encoding the membrane transporter MCT8. MCT8 facilitates transport of T3 and T4 across cell membranes, particularly the blood–brain barrier and selected neural-cell membranes. Loss of transport function creates tissue-specific thyroid-hormone deprivation and excess. (geest2021monocarboxylatetransporter8 pages 4-5, geest2021monocarboxylatetransporter8 pages 5-6)

Risk factors

Genetic: hemizygosity for a pathogenic SLC16A2 allele in males. Variant classes include whole-gene or multiexon deletions, frameshift, nonsense, splice-altering, and pathogenic missense variants. Approximately 150 distinct disease-associated variants in roughly 250 families had been reported by 2021. (geest2021monocarboxylatetransporter8 pages 5-6)
Family history: a heterozygous carrier has a 50% probability of transmitting the variant in each pregnancy; sons inheriting it are generally affected, while daughters are usually carriers.
Sex: males are overwhelmingly affected because the disorder is X-linked. Rare symptomatic females have been reported with skewed X-inactivation or X-chromosomal rearrangement. (moran2022geneticdisordersof pages 4-5, bauer2024unmetpatientneeds pages 5-6)
De novo occurrence/germline mosaicism: possible; absence of family history does not exclude AHDS. (bauer2024unmetpatientneeds pages 5-6)

No reproducible environmental, infectious, toxic, occupational, dietary, smoking, or lifestyle cause is known. Consanguinity is not intrinsically relevant to this X-linked condition. No GWAS susceptibility architecture is expected for a monogenic disorder.

Protective and modifier factors

No validated protective allele, modifier gene, diet, or lifestyle intervention prevents disease in a person carrying a fully pathogenic allele. Residual MCT8 transport activity can moderate severity: truncating variants and large deletions generally produce severe disease, whereas some missense variants retain transport. Not every rare missense change is pathogenic, and C-terminal substitutions beyond Met574 of the long isoform may be tolerated. Functional assays are therefore important. (beheshti2022allanherndondudleysyndromea pages 1-2, geest2021monocarboxylatetransporter8 pages 5-6, geest2021monocarboxylatetransporter8 pages 10-11)

There is no established gene–environment interaction. Nutrition, aspiration prevention, cardiac surveillance, and therapy can modify complications and survival but do not alter the inherited cause.

3. Phenotypes

Neurologic and developmental phenotype

Symptoms are generally absent or nonspecific at birth and emerge at approximately 2–4 months, with hypotonia, poor head control, delayed milestones, and poor weight gain. Development is chronically and severely impaired. In a large cohort, motor and cognitive scores plateaued at a developmental age well below 12 months despite a median chronological evaluation age of 6.4 years. Only 4 of 77 individuals in the larger international cohort acquired walking. (geest2021monocarboxylatetransporter8 pages 6-7, bauer2024unmetpatientneeds pages 3-5)

Key findings and suggested HPO annotations are:

Global developmental delay/severe intellectual disability: almost universal, severe, lifelong; HP:0001263, HP:0001249.
Central hypotonia and poor head control: early and severe; hypotonia occurred in 100% of a 24-person cohort; HP:0001252, HP:0001290.
Spasticity/spastic quadriplegia: frequently emerges later as hypotonia evolves; 71% in one cohort; HP:0001257.
Dystonia and mixed movement disorder: 75% in one cohort; may include chorea, athetosis, bradykinesia, paroxysmal dyskinesia, and exaggerated startle; HP:0001332, with more specific movement terms as documented. (geest2021monocarboxylatetransporter8 pages 5-6, bauer2024unmetpatientneeds pages 3-5)
Absent or profoundly impaired speech: common; HP:0001344/appropriate expressive-language term.
Seizures: approximately 25%, generally less frequent than the movement disorder; HP:0001250. (moran2022geneticdisordersof pages 4-5)
Persistent primitive reflexes: characteristic clinical clue; HP:0002496 where applicable.

Quality-of-life effects are profound: most patients are nonverbal, wheelchair-dependent, and reliant on caregivers for all activities of daily living. Caregiver priorities in a 22-person survey were developmental gains (100%), head control (59%), sitting (50%), weight gain (36%), expressive language (32%), dysphagia or reflux improvement (27% each), and reduced dystonia/spasticity (18%). (bauer2024unmetpatientneeds pages 6-7)

Neuroimaging and myelin

MRI commonly shows diffuse delayed myelination or hypomyelination, particularly in deep anterior white matter before age five; 19/24 patients in one series were affected, and approximately half had global cerebral atrophy. Some conventional MRI studies suggest improvement with age, whereas postmortem and advanced imaging indicate persistent microstructural myelin abnormalities. The most accurate current interpretation is developmentally delayed and potentially incomplete myelination, with heterogeneity by age and method. Suggested HPO: HP:0002188, delayed CNS myelination. (vancamp2020monocarboxylatetransporter8 pages 1-2, geest2021monocarboxylatetransporter8 pages 5-6, bauer2024unmetpatientneeds pages 5-6)

Endocrine, nutritional, and gastrointestinal phenotype

Peripheral thyrotoxicosis causes hypermetabolism superimposed on neurologic feeding impairment.

Low body weight/failure to thrive: underweight in 71%; HP:0004325, HP:0001508.
Hypotrophic musculature/muscle wasting: 84%; HP:0003202.
Dysphagia/impaired swallowing: 71%, with aspiration risk; HP:0002015.
Feeding difficulty, gastroesophageal reflux, gastroparesis, constipation: common; HP:0011968, HP:0002020, HP:0002019.
Increased sweating and heat production: compatible with systemic T3 excess; HP:0000975 where documented.

The characteristic laboratory abnormalities in the international cohort were elevated T3 in 95%, low free T4 in 89%, low total T4 in 90%, low rT3 in 91%, and age-normal TSH in 89%; all tested patients had a high T3:rT3 ratio. (geest2021monocarboxylatetransporter8 pages 5-6)

Cardiovascular, respiratory, and skeletal phenotype

Premature atrial contractions occurred in 76%, elevated systolic blood pressure in 53%, and resting tachycardia in 31%. Conduction abnormalities and sudden death raise concern for arrhythmic mortality. Suggested HPO: HP:0001649 tachycardia, HP:0000822 hypertension, and the specific arrhythmia term documented by ECG. (geest2021monocarboxylatetransporter8 pages 6-7, persani20242024europeanthyroid pages 13-14)

Recurrent pulmonary infection and aspiration pneumonia are major complications. Scoliosis, hip subluxation/dislocation, and osteoporosis develop from abnormal tone, immobility, malnutrition, and endocrine effects. Suggested terms include HP:0002650 scoliosis, HP:0002827 hip dislocation, and HP:0000939 osteoporosis. (persani20242024europeanthyroid pages 13-14)

4. Genetic and molecular information

Gene and protein

Gene: SLC16A2; approved protein name monocarboxylate transporter 8/MCT8.
Disease mechanism: germline loss of function or marked reduction in thyroid-hormone transport.
Origin: constitutional/germline, not a somatic cancer mechanism.
Variant spectrum: deletions, frameshift and nonsense truncation, splice variants, in-frame indels, and missense variants. Population frequencies should be assessed variant-by-variant in gnomAD; pathogenic severe alleles are expected to be absent or extremely rare. No single allele frequency can characterize the disease.
Classification: apply ACMG/AMP criteria using phenotype, segregation, absence from population databases, predicted consequence, and functional transport evidence. ETA recommends that an SLC16A2 VUS be evaluated with family segregation, testing in transfected or patient-derived cells, and structural modeling; computational prediction alone is insufficient. (persani20242024europeanthyroid pages 5-6)

Genotype–phenotype relationship

Large deletions and truncating variants generally confer severe disease. Missense variants range from complete loss to appreciable residual function and can produce milder phenotypes. Functional testing in an appropriate cell system is essential because some overexpression systems misclassify membrane trafficking or residual transport. Chemical-chaperone responsiveness is likewise mutation-specific. (geest2021monocarboxylatetransporter8 pages 7-9, geest2021monocarboxylatetransporter8 pages 5-6)

No independently validated modifier gene or disease-specific epigenetic signature is established. Rare structural rearrangements involving the X chromosome can cause disease in females by disrupting SLC16A2 or altering X-inactivation. Genetic anticipation is not a feature.

5. Environmental information

AHDS is not caused by toxins, radiation, pollution, occupation, lifestyle, or an infectious agent. Environmental and care-related factors instead influence complications: inadequate caloric intake and dysphagia worsen underweight; immobility worsens skeletal health; aspiration promotes pneumonia; and delayed recognition postpones supportive and targeted therapy. No vaccine, anti-infective prophylaxis, or exposure avoidance prevents the molecular disease.

6. Mechanism and pathophysiology

Upstream causal chain

Pathogenic SLC16A2 allele → absent/reduced MCT8 protein or membrane transport → impaired T3/T4 transfer across brain endothelium and selected neural membranes → intracellular thyroid-hormone deficiency during fetal and postnatal brain development → deficient nuclear thyroid-receptor signaling → abnormal progenitor proliferation/differentiation, neuronal migration, axonal maturation, synaptogenesis, oligodendrocyte maturation, and myelination → severe motor, cognitive, and movement disorder. (salaslucia2024impairedt3uptake pages 1-2, geest2021monocarboxylatetransporter8 pages 4-5)

Human postmortem evidence is especially important: fetal and 11-year-old brain showed delayed cortical/cerebellar development, altered Purkinje-cell dendritogenesis, low MBP, and impaired axonal maturation; cerebral T3 and T4 were approximately 50% lower. These findings demonstrate prenatal onset and argue against complete spontaneous neural recovery. (geest2021monocarboxylatetransporter8 pages 4-5)

Suggested GO biological processes include thyroid hormone transport, response to thyroid hormone, regulation of transcription by RNA polymerase II, neurogenesis, neuron differentiation, axonogenesis, synapse organization, oligodendrocyte differentiation, and CNS myelination. Relevant cell types include brain microvascular endothelial cells, neurons, neural progenitors, oligodendrocyte precursor cells, mature oligodendrocytes, astrocytes, tanycytes, Purkinje neurons, and pituitary folliculostellate cells. High-confidence CL mappings should be curated against the current Cell Ontology release rather than inferred from names alone.

Peripheral thyrotoxicosis and biochemical signature

Outside the CNS, alternative thyroid-hormone transporters permit uptake of elevated serum T3. MCT8 deficiency may trap T4 in renal proximal-tubule cells, increase DIO1 activity and T4-to-T3 conversion, and contribute to high serum T3 with low T4/rT3. Altered thyroidal secretion and hypothalamic–pituitary feedback may also contribute. The renal mechanism is compelling in mice but is not fully resolved in humans. (geest2021monocarboxylatetransporter8 pages 4-5, geest2021monocarboxylatetransporter8 pages 5-6)

Downstream excess T3 signaling drives increased catabolism, low weight, muscle loss, tachycardia, blood-pressure abnormalities, high SHBG, low cholesterol/creatinine, and enhanced bone turnover. This explains the paradox of a hypothyroid brain within a systemically thyrotoxic organism.

Molecular profiling and 2024 development

Patient-derived cerebral organoids provided direct human, species-relevant evidence in 2024. MCT8-deficient organoids had smaller neural rosettes, thinner cortical units, impaired T3 transport, reduced T3-responsive transcription, and altered genes involved in cortical development, migration, astrocyte biology, myelin, neurotransmission, ion channels, and extracellular matrix. D3-mediated T3 metabolism was 5.3 ± 3.1 pmol/mg/h versus 18.4 ± 7.7 in controls—about 30% of wild type. TRIAC and DITPA restored induction or repression of T3-responsive genes despite nonfunctional MCT8. (salaslucia2024impairedt3uptake pages 4-5, salaslucia2024impairedt3uptake pages 1-2, salaslucia2024impairedt3uptake pages 9-10)

Direct abstract statement: “MCT8-deficient COs represent a species-specific relevant preclinical model that can be utilized to screen drugs with potential benefits as personalized therapeutics for patients with AHDS.” [Salas-Lucia et al., published February 20, 2024; DOI: https://doi.org/10.1172/jci.insight.174645]. (salaslucia2024impairedt3uptake pages 1-2)

No mature disease-specific single-cell atlas, spatial-transcriptomic dataset, proteomic signature, lipidomic biomarker, or integrated human multi-omic classifier was identified. The organoid RNA-seq work is currently the clearest advanced molecular-profiling evidence.

7. Anatomical structures affected

Organ and tissue levels

Primary: CNS—cerebral cortex, white matter, basal ganglia/dopaminergic circuits, corticospinal pathways, cerebellum/Purkinje cells, and brain barriers.
Secondary/peripheral: skeletal muscle, heart and conduction system, kidney, liver, bone, gastrointestinal tract, lungs through aspiration, and thyroid/hypothalamic–pituitary axis.
Suggested UBERON concepts: brain, cerebral cortex, cerebral white matter, basal ganglion, cerebellum, blood–brain barrier, spinal cord, skeletal muscle tissue, heart, kidney, liver, bone, esophagus, stomach, and lung. Exact IDs should be resolved against the current UBERON release during ingestion.

At the subcellular level, MCT8 is a multi-pass plasma-membrane transporter. Missense variants may cause misfolding, defective membrane trafficking, instability, or impaired substrate transport. Relevant GO cellular components are plasma membrane, blood–brain-barrier endothelial membrane, axon, neuronal cell body, myelin sheath, and nucleus downstream of thyroid-receptor signaling. There is no characteristic lateralization; CNS and systemic effects are bilateral/diffuse.

8. Temporal development

AHDS is congenital genetically and pathophysiologically, with prenatal brain vulnerability, but clinical signs often become recognizable only after 2–4 months. Median diagnosis was 24 months (IQR 12–60), with an 18-month median symptom-to-diagnosis delay (IQR 7.8–63). (bauer2024unmetpatientneeds pages 3-5)

The course is chronic and lifelong. A useful clinical staging framework is:

Prenatal/neonatal: impaired neural thyroid signaling; routine screening usually negative.
Early infancy: hypotonia, poor head control, feeding difficulty, failure to thrive.
Childhood: severe milestone limitation, dystonia, evolving spasticity, hypomyelination, increasing nutritional and orthopedic burden.
Adolescence/adulthood: persistent profound disability, contractures/scoliosis, low weight, cardiopulmonary complications, and premature mortality.

There is no spontaneous remission. Some conventional MRI myelination appearances improve, but functional recovery is usually very limited. The critical treatment period begins during fetal neurogenesis and likely declines across the first three years, whereas peripheral thyrotoxicosis remains treatable at any age. (persani20242024europeanthyroid pages 13-14, bauer2024unmetpatientneeds pages 6-7)

9. Inheritance and population

AHDS is X-linked and predominantly affects males. Penetrance in males with clearly loss-of-function alleles appears high, but expressivity varies with residual transport. Heterozygous females are usually asymptomatic or mildly affected because of random X-inactivation; skewed X-inactivation or structural X abnormalities can cause overt disease. (bauer2024unmetpatientneeds pages 5-6)

Published epidemiology is imprecise. Earlier reviews cited fewer than one case per million and approximately 320 diagnosed patients; genetic/natural-history analyses suggest approximately 1 per 70,000 males, indicating substantial underdiagnosis. No reliable annual incidence, population carrier frequency, ethnic enrichment, endemic geography, or broad founder effect has been established. (grijotamartinez2020mct8deficiencythe pages 1-2, moran2022geneticdisordersof pages 4-5)

There is no evidence for anticipation. Germline mosaicism is possible. Geographic case distribution largely reflects access to pediatric neurology, endocrine testing, sequencing, and specialist networks rather than biologic restriction.

10. Diagnostics

Clinical and laboratory diagnosis

The 2024 ETA guideline recommends full neurologic and physical assessment plus age-adjusted serum free/total T3, free/total T4, rT3, and TSH. Major criteria are the characteristic biochemical pattern plus global developmental delay, hypomyelination, movement disorder, persistent primitive reflexes, or family history. (persani20242024europeanthyroid pages 5-6)

Useful additional tests include:

SHBG, creatinine, CK, cholesterol, and ALT as peripheral thyroid-action markers.
Nutritional assessment and serial weight, every three months in infants/children.
ECG, Holter/telemetry, blood pressure, and echocardiography where indicated.
Swallow evaluation and videofluoroscopic study for aspiration.
Brain MRI for myelination and atrophy.
EEG for suspected seizures—not for most paroxysmal dystonia/startle events by default.
Spine/hip radiography and DXA for orthopedic/bone complications. (persani20242024europeanthyroid pages 13-14)

Genetic testing strategy

Known familial variant: targeted SLC16A2 testing.
Classic biochemical/clinical presentation: SLC16A2 sequencing plus deletion/duplication analysis.
Nonspecific developmental disorder: neurodevelopmental, leukodystrophy, or thyroid-signaling panel that explicitly includes SLC16A2.
Unresolved case: WES or WGS with copy-number analysis; WGS can additionally detect regulatory/intergenic and complex structural variants.
CMA can detect large Xq13 deletions but does not exclude sequence-level disease. Karyotyping/FISH are reserved for suspected rearrangements, especially affected females. Mitochondrial and repeat-expansion testing are not disease-specific. (bauer2024unmetpatientneeds pages 5-6)

RNA studies or patient-cell transport assays can clarify splice variants and VUSs. Proteomics, metabolomics, epigenomics, and liquid biopsy are not established diagnostic methods.

Differential diagnosis

Important alternatives include cerebral palsy, Pelizaeus–Merzbacher and Pelizaeus–Merzbacher-like disorders, MECP2 duplication syndrome, mitochondrial disease, other leukodystrophies, congenital hypothyroidism, and resistance to thyroid hormone alpha. RTHα is the closest biochemical mimic, but tends toward bradycardia and skeletal dysplasia, whereas MCT8 deficiency produces tachycardia, hypermetabolism, and failure to thrive. (bauer2024unmetpatientneeds pages 3-5)

Screening

Routine TSH- or T4-based newborn screening misses AHDS because T3 elevation develops later. Among eight patients with historical T4 newborn-screening data, 88% had T4 below the 20th percentile but none was identified; TSH screening would also have been negative. Low neonatal rT3 and an elevated T3:rT3 ratio are candidate biomarkers, but rT3 availability and assay standardization limit implementation. (geest2021monocarboxylatetransporter8 pages 5-6, bauer2024unmetpatientneeds pages 3-5)

11. Outcome and prognosis

Median survival in the international natural-history cohort was approximately 35 years. About 30% die in childhood in published summaries; among the most severely affected, childhood mortality approached 50%. Pulmonary infection, aspiration pneumonia, and sudden death—possibly arrhythmic—are major causes. (moran2022geneticdisordersof pages 4-5, geest2021monocarboxylatetransporter8 pages 6-7)

Early underweight at ages 1–3 and failure to acquire head control by 1.5 years are adverse prognostic markers. These reflect peripheral thyrotoxicosis/nutritional compromise and neurologic severity, respectively. No validated molecular prognostic biomarker beyond residual variant function is established. (geest2021monocarboxylatetransporter8 pages 6-7)

Recovery to independent function is uncommon. Morbidity includes lifelong dependence, absent speech and ambulation in most, dysphagia, malnutrition, aspiration, contractures, scoliosis, osteoporosis, sleep disturbance, and repeated specialist/hospital care. A completed 21-caregiver multinational study measured economic burden, EQ-5D-5L, PedsQL Family Impact, and proxy patient QoL, but numerical results were not available in the retrieved record. [NCT06060197, posted September 29, 2023; https://clinicaltrials.gov/study/NCT06060197]. (NCT06060197 chunk 1)

12. Treatment

Current strategy and expert guidance

Treatment should combine control of peripheral thyrotoxicosis with intensive multidisciplinary supportive care. The 2024 ETA guideline strongly recommends TRIAC/tiratricol and weakly recommends DITPA; postnatal levothyroxine monotherapy is not recommended. TRIAC or DITPA should be titrated toward serum T3 of 1.4–2.5 nmol/L, unless dose-related toxicity intervenes. Assay cross-reactivity with TRIAC can distort immunoassay T3; LC-MS/MS is preferred where available. (persani20242024europeanthyroid pages 5-6, persani20242024europeanthyroid pages 13-14)

Tiratricol/TRIAC

TRIAC (3,3′,5-triiodothyroacetic acid; tiratricol) enters cells independently of MCT8 and activates thyroid receptors. In Triac Trial I, 46 were enrolled, 45 had follow-up, and 40 completed 12 months. Serum T3 fell and body weight, heart rate/rhythm, blood pressure, SHBG, and creatinine improved. Benefits persisted during extension treatment; serious drug-related adverse events were not observed, although transient biochemical thyrotoxicosis occurred in a small subset. Neurologic improvement was not proven overall, but younger children showed a favorable trend. [PMID 31377265; published July 31, 2019; DOI: https://doi.org/10.1016/S2213-8587(19)30155-X]. (geest2021monocarboxylatetransporter8 pages 7-9, NCT02060474 chunk 2)

A long-term combined cohort of 67 patients found 60/67 (90%) maintained T3 within target, including patients treated beyond two years. A four-patient Argentine real-world series reported lower T3 in all, weight gain in two malnourished children, and improvements in tone/development, but uncontrolled observations cannot establish neurologic efficacy. (bauer2024unmetpatientneeds pages 6-7)

Relevant trials/implementation:

NCT02060474, Triac Trial I: completed phase II, n=46. https://clinicaltrials.gov/study/NCT02060474. (NCT02060474 chunk 1)
NCT02396459, Triac Trial II: open-label phase II, n=22 boys treated by ≤30 months, assessing GMFM-88, Bayley-III, HINE, thyroid and cardiac outcomes through five years. https://clinicaltrials.gov/study/NCT02396459. (NCT02396459 chunk 1, NCT02396459 chunk 2)
NCT05579327, ReTRIACt: randomized quadruple-masked phase III withdrawal study, actual n=20, designed to test whether stopping tiratricol causes T3 rebound. https://clinicaltrials.gov/study/NCT05579327. (NCT05579327 chunk 1)
NCT05911399: U.S. expanded-access program, using 350-µg tablets orally or by PEG/NG/jejunal tube. https://clinicaltrials.gov/study/NCT05911399. (NCT05911399 chunk 1)

Suggested NCIT intervention concepts: tiratricol/thyroid-hormone analog therapy, oral drug administration, enteral-tube administration, physical therapy, occupational therapy, speech-language therapy, nutritional support, and genetic counseling; exact NCIT codes should be resolved against the current NCIT release.

DITPA

DITPA (3,5-diiodothyropropionic acid) bypasses MCT8 and binds thyroid receptors, but has substantially weaker TRβ affinity than T3. Four children treated compassionately for a median 38.5 months normalized T3 and TSH and showed some peripheral improvement, but no neurocognitive benefit. It remains less strongly supported than TRIAC. (geest2021monocarboxylatetransporter8 pages 7-9, bauer2024unmetpatientneeds pages 6-7)

Conventional thyroid drugs

Levothyroxine alone can further increase T3 and worsen peripheral thyrotoxicosis without entering the MCT8-dependent brain. LT4 plus PTU reduced T3, heart rate, and SHBG and improved weight in five reported patients but did not improve neurodevelopment. PTU carries clinically important risks of agranulocytosis and severe hepatic failure; the 2024 guidance therefore favors analog therapy. (geest2021monocarboxylatetransporter8 pages 6-7, bauer2024unmetpatientneeds pages 5-6)

Supportive and rehabilitative care

Care should include endocrinology, neurology, clinical genetics, cardiology, gastroenterology/nutrition, respiratory care, orthopedics, physiotherapy, occupational therapy, speech/augmentative communication, swallowing therapy, social work, and palliative-care expertise when appropriate. Interventions include calorie optimization, gastrostomy when oral feeding is unsafe/inadequate, reflux/constipation management, aspiration precautions, vaccination and prompt respiratory treatment, dystonia/spasticity management, seizure therapy when present, positioning/assistive devices, scoliosis/hip surveillance, and sleep support. Evidence for specific symptomatic regimens in AHDS is limited. (persani20242024europeanthyroid pages 13-14, bauer2024unmetpatientneeds pages 5-6)

Registry evidence reveals implementation gaps: only 19% had pediatric gastroenterology involvement, 31% received dietitian advice, 12.5% of those reporting feeding problems had a feeding tube, 6% had pediatric cardiology involvement, and one in five did not receive regular physical therapy. (bauer2024unmetpatientneeds pages 5-6)

Experimental therapeutics

Glycerol phenylbutyrate: intended as a chemical chaperone for selected misfolded MCT8 variants. NCT05019417 proposed up to six patients with escalating Ravicti dosing, but registry status was unknown and efficacy is unproven. https://clinicaltrials.gov/study/NCT05019417. (NCT05019417 chunk 1)
Gene therapy: IV AAV9-hMCT8 and BBB-targeted AAV-BR1-Mct8 increase brain T3 and improve motor phenotypes in mice. No human gene-therapy trial was identified. (maitykumar2022validationofmct8oatp1c1 pages 8-9, bauer2024unmetpatientneeds pages 7-8)
Sobetirome/Sob-AM2: MCT8-independent thyromimetics reach fetal brain in mice, but maternal Sob-AM2 was associated with spontaneous abortions; not ready for clinical use. (bauer2024unmetpatientneeds pages 8-9)
Prenatal treatment: one intra-amniotic high-dose LT4 case beginning at gestational week 17 suggested possible benefit; prenatal DITPA has been explored under compassionate-access protocols. These remain experimental and should occur only in specialist research settings. (geest2021monocarboxylatetransporter8 pages 9-10, persani20242024europeanthyroid pages 13-14)

No pharmacogenomic dosing guideline, cell therapy, immunotherapy, surgery that modifies the molecular disease, or approved CRISPR/RNA therapy exists.

13. Prevention

There is no lifestyle or environmental primary prevention after conception because AHDS is genetic. Primary prevention at the family level consists of genetic counseling, carrier testing, reproductive planning, preimplantation genetic testing, and prenatal diagnosis once a familial variant is known. ETA suggests SLC16A2 testing by chorionic-villus sampling or amniocentesis in an at-risk male fetus. (persani20242024europeanthyroid pages 5-6)

Secondary prevention is early recognition through family cascade testing, developmental surveillance, complete thyroid testing including T3/rT3, and rapid genetic confirmation. Universal newborn screening is not currently established. Tertiary prevention includes aspiration reduction, nutritional support, cardiac monitoring, bone/orthopedic surveillance, vaccination, rehabilitation, and targeted reduction of T3 excess. There is no disease-specific immunization or antimicrobial prophylaxis.

14. Other species and natural disease

The causal pathway is evolutionarily conserved, but no well-established, naturally occurring veterinary counterpart was identified in the retrieved evidence. Accordingly, breed-specific VBO terms, animal incidence, and veterinary management cannot be assigned. The condition is neither infectious nor zoonotic and has no cross-species transmission.

Orthologs include murine Slc16a2/Mct8 and zebrafish slc16a2/mct8. Species differ substantially in compensatory brain transporters—especially murine Oatp1c1—which explains why ordinary Mct8-null mice do not reproduce the severe human neurologic phenotype. (maitykumar2022validationofmct8oatp1c1 pages 1-2)

15. Model organisms and experimental systems

Mouse

The Mct8 single-knockout mouse reproduces the abnormal serum thyroid profile and impaired cerebral T3 entry but has relatively preserved brain development because Oatp1c1 transports T4 into the murine brain. It is useful for endocrine and renal mechanism studies but limited for human neurologic translation. (maitykumar2022validationofmct8oatp1c1 pages 1-2)

The Mct8/Oatp1c1 double-knockout mouse is the principal mammalian model. A 2022 CRISPR-generated line showed reduced survival, central hypothyroidism, peripheral hyperthyroidism, impaired myelination and motor performance, and excessive thyroid action in liver, adipose tissue, muscle, and bone. Viral restoration of Mct8 increased CNS T3 and improved motor function. Direct abstract statement: “Mct8/Oatp1c1 dKO mice mimic key hallmarks of the AHDS.” [Published October 18, 2022; DOI: https://doi.org/10.1016/j.molmet.2022.101616]. (maitykumar2022validationofmct8oatp1c1 pages 1-2, maitykumar2022validationofmct8oatp1c1 pages 8-9)

Zebrafish

The mct8−/− zebrafish develops hypomyelination and is useful for rapid developmental and drug screening. TRIAC completely rescued myelination and DITPA partially restored it in larval studies; Mct8 transgene expression also rescued the phenotype. (geest2021monocarboxylatetransporter8 pages 7-9)

Human cellular models

Patient-derived iPSC blood–brain-barrier models demonstrate reduced transendothelial T3 transport, directly supporting MCT8’s barrier role. Neural and oligodendroglial systems permit variant-functional assays and testing of analogs or chemical chaperones. (geest2021monocarboxylatetransporter8 pages 4-5)

The 2024 patient-derived cerebral organoid model is currently the strongest human developmental platform. It captures neural-progenitor, cortical, astroglial, and oligodendroglial abnormalities, supports RNA-seq profiling, and demonstrates MCT8-independent rescue of thyroid-responsive transcription by TRIAC and DITPA. Limitations include organoid heterogeneity, incomplete maturation and vasculature, and supraphysiologic T3 exposure. (salaslucia2024impairedt3uptake pages 4-5, salaslucia2024impairedt3uptake pages 9-10)

Evidence gaps and curation cautions

Prevalence ranges from historical diagnosed-case estimates below 1/million to modeled estimates near 1/70,000 males; underdiagnosis is likely.
Phenotype frequencies depend on ascertainment and age. The 24-person neurologic cohort overrepresented milder ambulant cases relative to the larger cohort.
No controlled evidence proves neurodevelopmental rescue in humans; apparent early-treatment gains require confirmation.
Variant pathogenicity must not be inferred from rarity or prediction alone.
Exact ORPHA, ICD, HGNC, GO, CL, UBERON, CHEBI, and NCIT identifiers not directly verified in the retrieved authoritative records should be resolved against current ontology releases before database ingestion.
No robust disease-specific epigenomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or natural-veterinary disease resource was identified.

Priority references

Persani L, et al. 2024 European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action. European Thyroid Journal. Published July 2024. DOI: https://doi.org/10.1530/ETJ-24-0125. (persani20242024europeanthyroid pages 5-6, persani20242024europeanthyroid pages 13-14)
Bauer AJ, et al. Unmet patient needs in monocarboxylate transporter 8 deficiency: a review. Frontiers in Pediatrics. Published July 2024. DOI: https://doi.org/10.3389/fped.2024.1444919. (bauer2024unmetpatientneeds pages 1-2, bauer2024unmetpatientneeds pages 5-6)
Salas-Lucia F, et al. Impaired T3 uptake and action in MCT8-deficient cerebral organoids underlie Allan-Herndon-Dudley syndrome. JCI Insight. Published February 20, 2024. DOI: https://doi.org/10.1172/jci.insight.174645. (salaslucia2024impairedt3uptake pages 1-2)
Groeneweg S, et al. Disease characteristics of MCT8 deficiency: an international retrospective multicentre cohort study. Lancet Diabetes & Endocrinology. 2020;8:594–605. DOI: https://doi.org/10.1016/S2213-8587(20)30153-4. (geest2021monocarboxylatetransporter8 pages 9-10)
Groeneweg S, et al. Effectiveness and safety of TRIAC in children and adults with MCT8 deficiency. Lancet Diabetes & Endocrinology. Published July 31, 2019. PMID: 31377265. DOI: https://doi.org/10.1016/S2213-8587(19)30155-X. (NCT02060474 chunk 2)
Maity-Kumar G, et al. Validation of Mct8/Oatp1c1 dKO mice as a model organism for AHDS. Molecular Metabolism. Published October 18, 2022. DOI: https://doi.org/10.1016/j.molmet.2022.101616. (maitykumar2022validationofmct8oatp1c1 pages 1-2)
van Geest FS, et al. MCT8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology. Published September 2021. DOI: https://doi.org/10.3389/fendo.2021.723750. (geest2021monocarboxylatetransporter8 pages 1-2)
Vancamp P, et al. MCT8 deficiency: delayed or permanent hypomyelination? Frontiers in Endocrinology. Published May 2020. DOI: https://doi.org/10.3389/fendo.2020.00283. (vancamp2020monocarboxylatetransporter8 pages 1-2)

References

(grijotamartinez2020mct8deficiencythe pages 1-2): Carmen Grijota-Martínez, Soledad Bárez-López, David Gómez-Andrés, and Ana Guadaño-Ferraz. Mct8 deficiency: the road to therapies for a rare disease. Frontiers in Neuroscience, Apr 2020. URL: https://doi.org/10.3389/fnins.2020.00380, doi:10.3389/fnins.2020.00380. This article has 55 citations and is from a peer-reviewed journal.
(persani20242024europeanthyroid pages 5-6): Luca Persani, Patrice Rodien, Carla Moran, W Edward Visser, Stefan Groeneweg, Robin Peeters, Samuel Refetoff, Mark Gurnell, Paolo Beck-Peccoz, and Krishna Chatterjee. 2024 european thyroid association guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action. European Thyroid Journal, Jul 2024. URL: https://doi.org/10.1530/etj-24-0125, doi:10.1530/etj-24-0125. This article has 55 citations and is from a peer-reviewed journal.
(geest2021monocarboxylatetransporter8 pages 6-7): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(persani20242024europeanthyroid pages 13-14): Luca Persani, Patrice Rodien, Carla Moran, W Edward Visser, Stefan Groeneweg, Robin Peeters, Samuel Refetoff, Mark Gurnell, Paolo Beck-Peccoz, and Krishna Chatterjee. 2024 european thyroid association guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action. European Thyroid Journal, Jul 2024. URL: https://doi.org/10.1530/etj-24-0125, doi:10.1530/etj-24-0125. This article has 55 citations and is from a peer-reviewed journal.
(bauer2024unmetpatientneeds pages 6-7): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(OpenTargets Search: Allan-Herndon-Dudley syndrome-SLC16A2): Open Targets Query (Allan-Herndon-Dudley syndrome-SLC16A2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(geest2021monocarboxylatetransporter8 pages 1-2): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(vancamp2020monocarboxylatetransporter8 pages 1-2): Pieter Vancamp, Barbara A. Demeneix, and Sylvie Remaud. Monocarboxylate transporter 8 deficiency: delayed or permanent hypomyelination? Frontiers in Endocrinology, May 2020. URL: https://doi.org/10.3389/fendo.2020.00283, doi:10.3389/fendo.2020.00283. This article has 47 citations.
(bauer2024unmetpatientneeds pages 1-2): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(moran2022geneticdisordersof pages 4-5): Carla Moran, Nadia Schoenmakers, W. Edward Visser, Erik Schoenmakers, Maura Agostini, and Krishna Chatterjee. Genetic disorders of thyroid development, hormone biosynthesis and signalling. Clinical Endocrinology, 97:502-514, Sep 2022. URL: https://doi.org/10.1111/cen.14817, doi:10.1111/cen.14817. This article has 77 citations and is from a peer-reviewed journal.
(geest2021monocarboxylatetransporter8 pages 5-6): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(bauer2024unmetpatientneeds pages 5-6): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(geest2021monocarboxylatetransporter8 pages 10-11): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(geest2021monocarboxylatetransporter8 pages 4-5): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(salaslucia2024impairedt3uptake pages 1-2): Federico Salas-Lucia, Sergio Escamilla, Antonio C. Bianco, Alexandra Dumitrescu, and Samuel Refetoff. Impaired t3 uptake and action in mct8-deficient cerebral organoids underlie allan-herndon-dudley syndrome. JCI Insight, Feb 2024. URL: https://doi.org/10.1172/jci.insight.174645, doi:10.1172/jci.insight.174645. This article has 21 citations and is from a domain leading peer-reviewed journal.
(bauer2024unmetpatientneeds pages 3-5): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(bauer2024unmetpatientneeds pages 7-8): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(NCT02060474 chunk 2): W. Edward Visser. Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients. Erasmus Medical Center. 2014. ClinicalTrials.gov Identifier: NCT02060474
(NCT05911399 chunk 1): Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency. Rare Thyroid Therapeutics International AB. ClinicalTrials.gov Identifier: NCT05911399
(NCT05579327 chunk 1): Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency). Rare Thyroid Therapeutics International AB. 2023. ClinicalTrials.gov Identifier: NCT05579327
(NCT02396459 chunk 1): Triac Trial II in MCT8 Deficiency Patients. Rare Thyroid Therapeutics International AB. 2020. ClinicalTrials.gov Identifier: NCT02396459
(geest2021monocarboxylatetransporter8 pages 7-9): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.
(NCT05019417 chunk 1): Amnon Zung. Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome). Kaplan Medical Center. 2021. ClinicalTrials.gov Identifier: NCT05019417
(maitykumar2022validationofmct8oatp1c1 pages 8-9): Gandhari Maity-Kumar, Lisa Ständer, Meri DeAngelis, Sooyeon Lee, Anna Molenaar, Lore Becker, Lillian Garrett, Oana V. Amerie, Sabine M. Hoelter, Wolfgang Wurst, Helmut Fuchs, Annette Feuchtinger, Valerie Gailus-Durner, Cristina Garcia-Caceres, Ahmed E. Othman, Caroline Brockmann, Vanessa I. Schöffling, Katja Beiser, Heiko Krude, Piotr A. Mroz, Susanna Hofmann, Jan Tuckermann, Richard D. DiMarchi, Martin Hrabe de Angelis, Matthias H. Tschöp, Paul T. Pfluger, and Timo D. Müller. Validation of mct8/oatp1c1 dko mice as a model organism for the allan-herndon-dudley syndrome. Molecular Metabolism, 66:101616, Dec 2022. URL: https://doi.org/10.1016/j.molmet.2022.101616, doi:10.1016/j.molmet.2022.101616. This article has 14 citations and is from a domain leading peer-reviewed journal.
(maitykumar2022validationofmct8oatp1c1 pages 1-2): Gandhari Maity-Kumar, Lisa Ständer, Meri DeAngelis, Sooyeon Lee, Anna Molenaar, Lore Becker, Lillian Garrett, Oana V. Amerie, Sabine M. Hoelter, Wolfgang Wurst, Helmut Fuchs, Annette Feuchtinger, Valerie Gailus-Durner, Cristina Garcia-Caceres, Ahmed E. Othman, Caroline Brockmann, Vanessa I. Schöffling, Katja Beiser, Heiko Krude, Piotr A. Mroz, Susanna Hofmann, Jan Tuckermann, Richard D. DiMarchi, Martin Hrabe de Angelis, Matthias H. Tschöp, Paul T. Pfluger, and Timo D. Müller. Validation of mct8/oatp1c1 dko mice as a model organism for the allan-herndon-dudley syndrome. Molecular Metabolism, 66:101616, Dec 2022. URL: https://doi.org/10.1016/j.molmet.2022.101616, doi:10.1016/j.molmet.2022.101616. This article has 14 citations and is from a domain leading peer-reviewed journal.
(salaslucia2024impairedt3uptake pages 4-5): Federico Salas-Lucia, Sergio Escamilla, Antonio C. Bianco, Alexandra Dumitrescu, and Samuel Refetoff. Impaired t3 uptake and action in mct8-deficient cerebral organoids underlie allan-herndon-dudley syndrome. JCI Insight, Feb 2024. URL: https://doi.org/10.1172/jci.insight.174645, doi:10.1172/jci.insight.174645. This article has 21 citations and is from a domain leading peer-reviewed journal.
(NCT06060197 chunk 1): MCT8 Deficiency Caregiver Study. Rare Thyroid Therapeutics International AB. 2022. ClinicalTrials.gov Identifier: NCT06060197
(bauer2024unmetpatientneeds pages 8-9): Andrew J. Bauer, Bethany Auble, Amy L. Clark, Tina Y. Hu, Amber Isaza, Kyle P. McNerney, Daniel L. Metzger, Lindsey Nicol, Samuel R. Pierce, and Richard Sidlow. Unmet patient needs in monocarboxylate transporter 8 (mct8) deficiency: a review. Frontiers in Pediatrics, Jul 2024. URL: https://doi.org/10.3389/fped.2024.1444919, doi:10.3389/fped.2024.1444919. This article has 12 citations.
(beheshti2022allanherndondudleysyndromea pages 1-2): Ramin Beheshti, Justen M. Aprile, and Charles Lee. Allan-herndon-dudley syndrome: a novel pathogenic variant of the slc16a2 gene. Cureus, Jan 2022. URL: https://doi.org/10.7759/cureus.21771, doi:10.7759/cureus.21771. This article has 8 citations.
(salaslucia2024impairedt3uptake pages 9-10): Federico Salas-Lucia, Sergio Escamilla, Antonio C. Bianco, Alexandra Dumitrescu, and Samuel Refetoff. Impaired t3 uptake and action in mct8-deficient cerebral organoids underlie allan-herndon-dudley syndrome. JCI Insight, Feb 2024. URL: https://doi.org/10.1172/jci.insight.174645, doi:10.1172/jci.insight.174645. This article has 21 citations and is from a domain leading peer-reviewed journal.
(NCT02060474 chunk 1): W. Edward Visser. Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients. Erasmus Medical Center. 2014. ClinicalTrials.gov Identifier: NCT02060474
(NCT02396459 chunk 2): Triac Trial II in MCT8 Deficiency Patients. Rare Thyroid Therapeutics International AB. 2020. ClinicalTrials.gov Identifier: NCT02396459
(geest2021monocarboxylatetransporter8 pages 9-10): Ferdy S. van Geest, Nilhan Gunhanlar, Stefan Groeneweg, and W. Edward Visser. Monocarboxylate transporter 8 deficiency: from pathophysiological understanding to therapy development. Frontiers in Endocrinology, Sep 2021. URL: https://doi.org/10.3389/fendo.2021.723750, doi:10.3389/fendo.2021.723750. This article has 42 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Allan–Herndon–Dudley Syndrome (MCT8 Deficiency): Comprehensive Disease-Characteristics Report

Executive summary

1. Disease information

Definition and identifiers

2. Etiology, risk, protection, and environment

Causal factor

Risk factors

Protective and modifier factors

3. Phenotypes

Neurologic and developmental phenotype

Neuroimaging and myelin

Endocrine, nutritional, and gastrointestinal phenotype

Cardiovascular, respiratory, and skeletal phenotype

4. Genetic and molecular information

Gene and protein

Genotype–phenotype relationship

5. Environmental information

6. Mechanism and pathophysiology

Upstream causal chain

Peripheral thyrotoxicosis and biochemical signature

Molecular profiling and 2024 development

7. Anatomical structures affected

Organ and tissue levels

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical and laboratory diagnosis

Genetic testing strategy

Differential diagnosis

Screening

11. Outcome and prognosis

12. Treatment

Current strategy and expert guidance

Tiratricol/TRIAC

DITPA

Conventional thyroid drugs

Supportive and rehabilitative care

Experimental therapeutics

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Mouse

Zebrafish

Human cellular models

Evidence gaps and curation cautions

Priority references

Artifacts